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ABSTRACT
Britt, Keith A. (M.S., Chemical and Biological Engineering)
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil 
Emulsion
Thesis directed by Professor Theodore W. Randolph and Professor Daniel K. 
Schwartz
 Silicone oil is a lubricant used for plunger depression in prefilled glass 
syringes. Many therapeutic protein products are stored in prefilled syringes and 
may be exposed to the silicone oil-water interface for up to 18-24 months. At the 
present, our understanding of how proteins interact with this interface remains 
poorly understood. In this work, the interaction of three humanized monoclonal 
antibodies (humAbs) with silicone oil emulsion was assessed in presence of sodium 
chloride, sucrose, Tween® 20, Tween® 80, and poloxamer 188. It was found that the 
amount of humAb adsorbed was antibody- and excipient-dependent. Once adsorbed, 
the tryptophan exposure to solvent resembled that of unfolded protein and was 
independent of the identity of different excipients present in the formulation buffer. 
Protein aggregation was not detected in solution. But, colloidal destabilization of 
silicone oil emulsion resulting from protein adsorption lowered the activation 
energy barrier to flocculation thereby enabling heterogeneous aggregates comprised 
of protein-coated silicone oil microdroplets to form. The size of these flocs was 
dependent on the solution ionic strength. Flocculation occurred in the presence of all 
excipients examined except in the presence of surfactant. In formulations 
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containing surfactant, there was competition between humAb and surfactant 
molecules for adsorption sites at the silicone oil-water interface. The results suggest 
that the kinetics of humAb displacement from the silicone oil interface was 
surfactant-dependent. Whether the mechanism of this replacement involved the 
formation of protein-surfactant complex remains uncertain.
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 FIGURE 4.1. Zeta potential of native humAbs. Data for humAb 1, humAb 2, 
 and humAb 3 are labeled accordingly. For each protein, there are four bars 
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 FIGURE 4.2. Zeta potential of silicone oil emulsion in buffer containing 
 humAb 1 and 0.03% (w/v) surfactant. (A) Tween® 20. (B) Tween® 80. (C) 
 poloxamer 188. For each plot, there are two sets of data:  No protein 
 present, O  Protein present. Symbols represent the arithmetic mean of three 
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 replicate samples. Error bars represent the standard error of the 
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 FIGURE 4.3. Zeta potential of silicone oil emulsion in buffer containing 
 humAb 2 and 0.03% (w/v) surfactant. (A) Tween® 20. (B) Tween® 80. (C) 
 poloxamer 188. For each plot, there are two sets of data:  No protein 
 present, O Protein present. Symbols represent the arithmetic mean of three 
 replicate samples. Error bars represent the standard error of the 
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 FIGURE 4.4. Zeta potential of silicone oil emulsion in buffer containing 
 humAb 3 and  0.03% (w/v) surfactant. (A) Tween® 20. (B) Tween® 80. (C) 
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 FIGURE 5.1. Example of visible particles that can form after protein is 
 incubated with silicone oil emulsion. Visible particles were observed after 
 incubation of humAb 1 in 10 mM L-histidine at pH 6.0 containing 0.01% (w/v) 
 sodium azide and 0.03% (w/v) Tween® 80 for 72 hours.
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“All the world is a laboratory to the inquiring mind.”" 
       ~Martin H. Fischer
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CHAPTER 1: MOTIVATION AND BACKGROUND LITERATURE
1.1   INTRODUCTION
! Therapeutic protein products are becoming more reputable and widespread in 
the pharmaceutical industry. In general, protein drugs are more effective at lower 
concentrations with less side effects than small molecule drugs.1.40 Many protein 
drugs are formulated as a liquid. In the development these formulations, stresses 
imposed during production, processing, shipping, storage, and delivery to patients 
can result in the formation of sub-visible and/or visible particles. 
 Pharmaceutical proteins are ubiquitously exposed to potentially hazardous 
interfaces. Interface-induced protein damage or aggregation can elicit deleterious 
effects by reducing drug efficacy, increasing anti-drug immunogenicity, and 
shortening shelf-life. Also, it is estimated that major pharmaceutical companies 
spend between $800 million and $1.2 billion in research and development to bring a 
new drug to the market. For these reasons, there is a growing need to understand 
the behavior of proteins at interfaces, making this an area of research that is 
actively being pursued
1.2   ANTIBODY STRUCTURE, FUNCTION, INSTABILITY, AND THERAPEUTIC 
POTENTIAL
1.2.1   Structure
 Antibodies are immunoglobulins. A single immunoglobulin is roughly Y-
shaped and consists of a variable (V) region and a constant (C) region1.22,1.40 (Figure 
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1.1). The variable region is found at the top of the Y and is also called the Fab 
region.1.22,1.40 The constant region is found at the stem of the Y and is also called the 
Fc region.1.22,1.40 There are five different classes of immunoglobulins: IgA, IgD, IgE, 
IgG, and IgM.  These classes of immunoglobulins differ in their constant regions 
which are denoted  ", #, $, !, and !, respectively1.22, 1.40. The variable regions can be 
divided into three hypervariable (HV) regions and four framework (FR) regions.1.22, 
1.40 Immunoglobulins can exist as monomers (IgD, IgE, IgG), dimers (IgA), or 
pentamers (IgM).1.22,1.40 Since IgGs are the most abundant and widely used 
immunoglobulins used as protein therapeutics and are the focus of this work, these 
immunoglobulins will be discussed in more detail in the following sections. 
 IgGs consist of two identical heavy (H) chains approximately 50 kDa and two 
identical light (L) chains approximately 25 kDa such that the overall molecular 
weight of the molecule is roughly 150 kDa.1.22,1.40 In general, there are a total of four 
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A. B.
FIGURE 1.1.   Representative images of an IgG. (A) Ribbon Model. Light chains are 
green and dark blue, heavy chains are light blue and orange, disulfide bonds are 
yellow, and oligosaccharide is red. (B) Y-shape Model. Different regions are labeled. 
Sources 1.41, 1.42.
disulfide bonds linking heavy and light chains and four intrachain disulfide bonds 
residing in each domain of the heavy and light chains.1.22,1.40 IgGs can further be 
classified based on their relative abundance in human plasma.1.22,1.40 These IgGs are 
referred to as IgG1, IgG2, IgG3, and IgG4 with different heavy chains denoted %1, 
%2, %3, and %4, respectively.1.22,1.40 In addition, there are two types of light chains 
denoted & and '.1.22,1.40 The ratio of &:' is species-dependent.1.40
 Antibodies are glycosylated. In IgGs, there is one oligosaccharide that is N-
linked to a conserved Asn 297.1.40 Also, there are often other areas on the 
immunoglobulin that are glycosylated. Due to differences in cell lines, bioreactor 
conditions, and downstream processing, purified antibodies have different 
glycosylation patterns.1.40 In addition, terminal processing and instabilities during 
processing result in a heterogeneous antibody population.1.40
 The major type of secondary structure in IgGs is (-sheets.1.40 These 
structures comprise roughly 70% of the molecule.1.40 Only a small portion of IgG 
tertiary structure has been identified. This structure is maintained by disulfide 
bonds and non-covalent interactions.1.40
1.2.2   Function
 There are two functional areas in IgGs located at the Fab and Fc regions. The 
Fab region serves as an antigen-binding site.1.40 More specifically, the exact antigen-
binding sites are located in the hypervariable regions with participation of the 
framework regions1.40. Antigen-binding is proposed to occur by an induced-fit 
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mechanism wherein 5-10 residues are thought to contribute significantly to the 
binding energy1.40. The functionality in the variable region is independent of the 
constant region.1.40 The Fc region has three main effector functions1.40: (1) It is 
recognized by receptors on immune effector cells thereby initiating antibody-
dependent cell cytotoxicities (ADCC), (2) It binds to complement to recruit activated 
phagocytes, and (3) It aids in its transportation to different parts of the body. Unlike 
the Fab region, the functionality of the constant region is affected by the variable 
region.1.40 In addition, proper glycosylation is important in the functionality of an 
antibody.1.40 Glycosylation can affect the conformation of the antibody thereby 
affecting antigen binding, influence the immunogencity of the antibody to the body 
once administered to patients, and affect its degradation rate.1.40
 In the development of early antibody therapies, antibodies were made in 
mice. As a result, an adverse side-effect of these antibody drugs was the production 
of human anti-mouse antibodies (HAMA).1.40 To try to minimize this unwanted 
immune response, chimeric antibodies that are 60-70% human made from mouse 
variable regions and human constant regions were developed.1.40 These antibodies 
still elicited the formation of human anti-chimeric antibodies (HACA).1.40 Again, to 
lessen to observed immune response in patients, humanized antibodies that are 
90-95% human were developed by replacing murine hypervariable regions with 
human hypervariable regions.1.40 Humanized antibodies have nearly the same 
immunogenic potential as completely human antibodies, but can still elicit the 
formation of human anti-human antibodies (HAHA).1.40
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1.2.3   Instability
 In general, antibodies are stable proteins under normal storage conditions.1.40 
However, like all proteins, antibodies are susceptible to physical and chemical 
degradation that can result in impaired protein functionality.
 Physical instabilities of antibodies can occur via denaturation and 
aggregation.1.40 Denaturation can occur as a result of temperature shifts and 
shearing forces.1.40 Similarly, aggregation rate depends on protein concentration, 
viscosity, ionic strength, pH, and temperature.1.40 Both denaturation and 
aggregation may occur as a result of agitation, long-term storage, multiple freeze-
thaw cycles, and lyophilization.1.40 In addition, exposure of antibodies to interfaces, 
like other proteins, results in surface adsorption which decreases the concentration 
of protein in solution and may result in surface-induced denaturation and/or 
aggregation1.3-1.4,1.7-1.9,1.13,1.15,1.18-1.20,1.23-1.24,1.26-1.27,1.32,1.34-1.37.
 Chemical instabilities of antibodies can occur via numerous pathways. These 
instabilities include cross-linking resulting from disulfide bond formation or 
exchange, deamidation, isomerization, oxidation, formation of acidic or basic 
species, C-terminal clipping, fragmentation, and/or the formation of protein-sugar 
adducts via the Maillard reaction1.40. The mechanisms by which said instabilities 
may occur can be attributed to storage conditions, dosage form, pH conditions, 
amino acid sequence, steric effects, temperature shifts, or freeze-thaw conditions.1.40
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1.2.4   Therapeutic Potential
 Antibodies can act as agonists or antagonists to potentially control major 
pathways in cancer, infectious diseases, allergy, autoimmune diseases, and 
inflammation.1.40 Currently, there are more than 23 monoclonal drug products on 
the market including humanized monoclonal antibody drug products such as 
Avastin®, Campath®, Herceptin®, Humira®, Lucentis®, Mylotarg®, Raptiva®, 
Synagis®, Tysabri®, Xolair®, and Zenapax®.1.40 Antibody and antibody derivatives 
constitute 20% of biopharmaceutical products currently being developed.1.40 
However, development of commercially viable antibody drug products is difficult. 
Despite having similar molecular weights, isoelectric points, and structures, the 
behavior of antibodies cannot be generalized. 
 In addition to liquid and lyophilized antibody formulations, advanced 
formulations have been attempted. Spray-dried formulations have been tested and 
limited success has been achieved due to the high propensity of proteins to 
aggregate.1.40 Stabilization of antibodies and antibody fragments via mutagenesis 
and chemical modification has had some success.1.40 There have been studies that 
saw noticeable increases in antibody stability.1.40 However, some studies have 
showed that chemical modification of antibodies resulted in increased clearance 
rates and reduced biodistribution.1.40 PEGlyation of antibodies has also been 
attempted and may be useful in some applications.1.40 However, this can reduce 
drug efficacy and can elicit an unwanted immune response.1.40
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1.3   PHARMACEUTICAL EXCIPIENTS
1.3.1   Definition of ‘Excipient’
 Historically, there have been several formal definitions of ‘excipient.’ Today, the 
International Pharmaceutical Excipients Council (IPEC) defines ‘excipient’  as any 
substance contained in the finished pharmaceutical dosage form other than the 
active drug or prodrug.1.10
1.3.2   Excipient Selection and Formulation Design
 Selection of suitable excipients to use in pharmaceutical formulations can be a 
daunting task. Excipients should be chemically stable, be non-reactive with the 
drug and other excipients, possess low toxicity in the human body, have low process 
and equipment sensitivity, have pleasing organoleptic properties, be well 
characterized, and be well accepted by regulatory agencies.1.10,1.28 The number of 
excipients that adhere to the aforementioned list of requirements is limited making 
selection of new excipients a challenging process. However, because some drugs 
have non-ideal physiochemical, permeation, and pharmacokinetic properties, new 
excipients or new applications of existing excipients have been developed.1.10 To 
date, there have been very few new excipients of completely new chemical identity 
introduced to the market because of the economic strain associated with 
toxicological screening.1.10,1.28
 The type of formulation and excipients used in a pharmaceutical product 
undergo extensive screening experiments to assess the conditions that a particular 
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protein drug will be stable for the longest period of time. Experiments may be 
conducted under ‘accelerated’ conditions to allow the behavior of a protein drug to 
be assessed for a shorter period of time. Once pre-formulation studies are performed 
to determine possible stabilization strategies, the typical order of experiments 
conducted to design the optimal formulation is listed as follows1.28:
(1) Obtain the stability profile of the protein solution containing no 
formulation excipients under ‘stressed’ conditions. Typical stresses include 
agitation and temperature.
(2) Obtain the stability profile of the same protein solutions with the same 
stresses in the presence of excipient(s). Select possible candidates that are 
the most stable protein formulations.
(3) Optimize the protein stability of candidate formulations.
(4) Perform real-time long-term protein stability studies of the optimized 
candidate formulations at a larger scale.
Aqueous formulations are preferred due to ease manufacturing and administration. 
Lyophilized formulations are chosen if the shelf-life of an aqueous solution is too 
low.1.28 The shelf-life of an economically viable protein therapeutic product ranges 
from 18-24 months. 
1.3.3   Excipient-Excipient and Drug-Excipient Interactions
 Excipient-excipient interactions and drug-excipient interactions can be 
favorable or unfavorable depending on the delivery strategy of the formulation. 
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These interactions can be classified as physical or chemical. Excipient-excipient and 
drug-excipient interactions can influence several different phenomena including 
adsorption, complexation, chemical reactions, pH shifts, and eutectic formation.1.10, 
1.28
1.3.4   Classes of Excipients used in Pharmaceutical Formulations
 
 There are several classes of excipients commonly utilized in pharmaceutical 
formulations including salts, sugars, polyols, amino acids, polymers, surfactants, 
and preservatives (see Table 1.1).1.10,1.28 The purpose of these excipients are to 
modulate solution tonicity, enhance protein stability, increase protein solubility, 
serve as a bulking agent, aid in the formation of a glassy state during lyophilization, 
or prevent microbial growth.1.10,1.28
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_____________________________________________________________            Class                               Purpose                            ___________________________________________________________________
Buffer            pH buffer                                
Salt           Tonicity modifier, solubilizer
Sugar           Protein-stabilizer, bulking agent, glass former
Polyol            Tonicity modifier, bulking agent
Amino Acid          Tonicity modifier, bulking agent, stabilizer
Polymer            Bulking agent, glass former
Surfactant            Solubilizer, stabilizer, aggregation inhibitor
Preservative        Antimicrobial  
___________________________________________________________________
TABLE 1.1. Class and purpose of common pharmaceutical excipients. 
Sources: 1.10, 1.28.
1.4   PROTEIN ADSORPTION TO INTERFACES
 Proteins have been shown to be surface-active at various interfaces.1.1,1.3-1.9,1.13, 
1.15,1.17-1.21,1.23-1.24,1.26,1.32,1.34-1.36,1.38 More specifically, protein adsorption has been 
observed at the solid-liquid interface1.4,1.6-1.8,1.20-1.21,1.36, the air-liquid interface1.1,1.3, 
1.5,1.14,1.17,1.26,1.34, and the liquid-liquid interface.1.18,1.23-1.24,1.35 While protein 
adsorption at solid substrates can be similar to that at fluid-fluid interfaces, there 
are differences. At the fluid-fluid interface, proteins can penetrate into the non-
aqueous phase, diffuse faster, and undergo faster orientational and conformational 
reorganization.1.15 Nearly all protein adsorption studies are characterized by non-
ideal behavior.1.15 This is due to enthalpic and entropic contributions to the surface 
free energy resulting from protein intermolecular interactions and intramolecular 
rearrangements.1.15
 The dynamics of protein adsorption at oil-water interface was investigated by 
Beverung et al. by monitoring the change in interfacial surface tension as a function 
of time using several model proteins.1.9 It was found that the kinetics of adsorption 
can be divided into three distinct regimes1.9: 
(1) An initial induction period that depends on diffusion of protein to an 
 interface and the affinity that protein has towards that interface. Only a 
a small change in interfacial tension is observed. Conformational 
rearrangement begins during this period. This regime is only observed for 
very dilute protein solutions. 
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(2) A period where the surface becomes saturated with adsorbed protein. 
There is continued conformational rearrangement. An increase in the 
number of interfacial contacts per protein causes a steep decline in 
interfacial tension. 
(3) The last period begins as a full monolayer is formed. Continued relaxation 
of the adsorbed protein layer and the onset of multilayer formation occurs 
in this regime.
 The phenomenology discussed thus far is relevant for an ensemble of protein 
molecules. Recently, techniques based on single-molecule total internal reflection 
fluorescence microscopy (TIRFM) have been developed to obtain more information 
about how protein adsorbs to interfaces.1.21,1.38 Honciuc et al. found that adsorption 
of individual surfactant molecules is an activated process that involves a 
competitive exchange between surfactant and surface-bound solvent molecules.1.21 
Walder et al. was able to identify multiple populations of fluorescently-labeled 
protein molecules that adsorb to the oil-water interface.1.38 For each population, the 
hydrodynamic radius, surface residence time, and the surface diffusion coefficient 
were determined. It was found that larger objects had longer surface residence 
times and smaller surface diffusion coefficients.
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1.5   PROTEIN AGGREGATION PATHWAYS
 
 Protein aggregation continues to be a problem in the commercialization of 
protein drug products. Aggregation can be classified as intrinsic or extrinsic.1.39 
Intrinsic protein aggregation results from changes in protein primary, secondary, 
tertiary, or quaternary structure.1.39 Extrinsic protein aggregation is influenced by 
the local environment of a protein during processing, storage, etc.1.39 There are 
several mechanisms/pathways by which protein aggregation can occur1.39:
(1) Aggregation through unfolding intermediates and unfolded states.
(2) Aggregation through protein self-association or chemical linkages.
(3) Aggregation through chemical degradations.
Aggregation can be reversible or irreversible.1.14,1.39 The reversibility of protein 
aggregation depends on the time scale at which aggregation occurs and the size of 
protein aggregates that are formed.1.39 Aggregate morphology (i.e. fibrils, 
particulates, skin, gels, or combinations of these) depends on these factors as well as 
pH, density of surface charge, and the degree of structural disruption.1.39
 There are several major stresses that may cause protein aggregation (see Table 
1.2).1.39 These stresses must overcome an electrostatic activation barrier to 
aggregation.1.14 The kinetics of protein aggregation for energy barriers greater than 
10-20 kT are extremely slow.1.14 If the energy barrier is overcome, partial/complete 
unfolding of protein, chemical degradation, shear, or disruption of hydration layers 
can occur leading to aggregation.1.39-1.40 Temperature shifts1.39-1.40, light or 
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irradiation1.39, container/closure systems1.20,1.24,1.39-1.40, and leachables1.6,1.39 can 
induce protein aggregation. Solution conditions including pH1.31,1.39-1.40, buffering 
agents,1.39-1.40 protein concentration1.39-1.40, solution ionic strength1.31,1.39-1.40, and 
formulation excipients may influence protein aggregation.1.28,1.39-1.40 Various 
processing steps may cause protein aggregation. These processing steps include 
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TABLE 1.2. Factors enhancing protein aggregation. Source: 1.39.
_________________________________________________________________________                     Factor                                                               Potential Effects _________________________________________________________________________
Temperature    -Partial/complete protein unfolding, protein-protein
       association, and chemical degradation
Light/Irradiation   -Chemical degradation, direct crosslinking of proteins
Container/Closure            -Surface protein adsorption, partial protein unfolding, 
Systems      and release of stability-influencing leachables
pH      -Partial/complete protein unfolding and alteration of 
       colloidal stability
Buffering agent and   -Variable effects depending on specificity and strength 
Concentration     ion-protein interactions and solution ionic strength
Ionic Strength    -Variable effects depending on charge screening, ion-
       protein interactions, and interference with protein-
       protein interactions
Excipients     -Variable effects depending on excipient type/purpose 
       and concentration
Protein Concentration  -High concentrations increase kinetics of protein-
       protein interactions and affects protein solubility
Fermentation/Expression  -Variable effects depending on expression of host 
       system and fermentation/expression conditions
Refolding     -Variable effects depending on refolding conditions,
       temperature, and protein concentration
Purification    -Variable effects depending on purification conditions
Freeze-thawing    -Ice-protein interactions, interfacial adsorption and 
       unfolding, cryoconcentration, cold denaturation, and 
       pH and ionic strength changes
Shaking     -Air-liquid interfacial adsorption and unfolding
Shearing     -Expose hydrophobic patches of protein
Pressurization    -Pressures > 100 MPa
Drying     -Loss of hydration layers disrupts protein structure
________________________________________________________________________________
fermentation/expression, refolding, purification, freeze-thawing, shaking, shearing, 
pressurization, and drying.1.39 Since proteins are structurally diverse, the relative 
effect of said factors on protein aggregation is protein-dependent.1.39 What may be a 
stable formulation for one protein may be unstable for another protein. For this 
reason, there is no universal strategy to prevent or inhibit protein aggregation.1.39
1.6   CONFORMATIONAL STABILITY OF THERAPEUTIC PROTEINS EXPOSED 
TO INTERFACEES
 Proteins can undergo orientational and conformational rearrangement at 
interfaces.1.15 Proteins that adsorb to hydrophobic surfaces and undergo appreciable 
conformational changes are referred to as “soft.”1.15,1.19 Conversely, proteins that 
experience little structural change are referred to as “hard.”1.15,1.19 Proteins tend to 
adsorb more extensively and irreversibly at hydrophobic surfaces than hydrophilic 
surfaces.1.15 At hydrophobic interfaces, a greater degree of protein unfolding leads to 
displacement of vicinal solvent molecules and the formation of strong interfacial 
hydrophobic interactions.1.15
 Protein conformational stability is highly surface and protein dependent.1.4, 
1.13-1.14,1.26 Upon adsorption, proteins can become “harder” or “softer.” Bee et al. found 
using front-face fluorescence quenching that HSA adsorbed to Alhydrogel® vaccine 
adjuvant particles became more structurally rigid.1.4 In the same study, Förster 
Resonance Energy Transfer (FRET) was used to determine that adsorbed HSA 
reoriented on the surface of adjuvant but did not unfold.1.4 Several studies have 
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been conducted to probe protein conformation at the air-water interface.1.26,1.32 
Using Infrared Reflection-Absorption Spectroscopy (IRRAS), Martin et al. and 
Schladitz et al. were able to identify changes in protein secondary structure upon 
adsorption.1.26,1.32 It was found that some proteins underwent no change in 
secondary structure, some lost secondary structure, and some gained secondary 
structure as a result of surface-induced protein aggregation.1.26,1.32 
 Protein denaturation and aggregation at an interface can occur with or without 
applied stresses.1.13,1.26,1.32 Soluble aggregates in bulk solution induced by protein 
adsorption to surfaces have been observed.1.1,1.5-1.7,1.17,1.34,1.36 Tyagi et al. and Bee et 
al. showed that stainless steel micro- and nanoparticles served as heterogeneous 
nucleation sites for soluble homogeneous protein aggregate formation.1.6-1.7,1.36 The 
results from Bee et al. suggested that aggregates observed in solution form after 
adsorption of protein multilayers.1.7 Insoluble aggregates have been observed as a 
result agitation of the air-water interface1.1,1.17,1.34 and the teflon-water interface.1.34 
Bee demonstrated that insoluble protein aggregates formed after compression of the 
air-water interface.1.5 It was found that the rate of aggregate formation increased 
with increasing interfacial compression.1.5 Bee also showed using air bubble 
tensiometry that relaxation of the adsorbed protein layer following compression of 
the air-water interface could be attributed to protein aggregation.1.3 In addition, 
Fesinmeyer et al. and Bam et al. found that agitation-induced aggregation at the 
air-water interface was enhanced by anion binding1.17 and reduced by Tween® 201.1, 
respectively. Sluzky et al. concluded that perturbation of the air-water interface 
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coupled with surface activity at the teflon-water interface resulted in protein 
aggregation.1.34
 Aggregation induced by protein adsorption to an interface is protein- and 
surface-dependent.1.1,1.3,1.5-1.8,1.17-1.18,1.20,1.23-1.24,1.34-1.36 Numerous studies have found 
that protein adsorbed to an interface without forming soluble or insoluble protein 
aggregates in solution.1.6,1.8,1.18,1.20,1.23-1.24,1.35 Bee et al. and Hoehne et al. showed that 
monoclonal antibodies adsorbed to glass1.6,1.20, cellulose1.6, Fe2O31.6, and tungsten1.8 
microparticles without forming homogeneous protein aggregates. The same finding 
was observed by Ludwig et al. and Gabrielson studying protein interactions with 
silicone oil emulsion.1.18, 1.24
!
1.7   PROBLEMS ASSOCIATED WITH PERTURBED PROTEIN CONFORMATION AND 
AGGREGATES
 The main problems associated with the processing and storage of therapeutic 
protein formulations are loss of drug activity1.27,1.37 or induction of an unwanted 
immune response.1.2,1.25,1.30  The root-cause of these problems may be associated with 
changes in protein conformation or protein aggregation. As was previously 
discussed, non-native denatured or aggregated protein may result from interactions 
with various interfaces as well as factors such as temperature1.39-1.40, pH1.31,1.39-1.40, 
ionic strength1.31,1.39-1.40, processing1.39, etc. (see Table 1.2).
 Loss of drug activity can jeopardize the proper treatment of a patient. 
Exposure of a protein drugs to contaminants such as steel1.6-1.7,1.36, tungsten1.8, 
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glass1.6,1.20, or silicone oil emulsion1.23-1.24,1.35 can be problematic, as previously 
discussed. However, even common equipment used routinely in hospitals can pose 
problems. Studies have shown than silicone rubber tubing decreased interleukin-2 
activity by 97%1.37 and PVC infusion bags decreased the activity of Factor VIII by 
42%.1.27 
 Another problem associated with protein therapeutics is the potential to 
induce unwanted immune responses.1.2,1.25,1.30 Currently, while there are many 
standard assays to detect immune responses of protein drugs in patients, there is no 
way to predict how a patient will respond to a drug. There is a complex interplay 
between an individual’s ability to mount an immune response versus that 
individual’s ability to tolerate certain antigens.1.2 At the moment, much more 
clinical data needs to be collected to know if its even possible to predict or eliminate 
unwanted immunogenicity of drug products. To make this task more difficult, 
proteins can partially unfold or aggregate before and after delivery to a patient. 
Maas et al. performed a study that showed that misfolded proteins enhance protein 
immunogenicity.1.25 Also, it has been shown that protein aggregates tend to be more 
potent than monomeric protein at eliciting responses from the immune system.1.30 
Factors influencing enhanced immune responses of protein aggregates include 
molecular weight, solubility, product origin, the presence of immunomodulatory 
contaminants, the presence of neoepitopes, heterogeneity in glycosylation patterns, 
and PEGlyation.1.30 The severity of a patient’s immune response to a drug product is 
variable. Possible outcomes of unwanted immune responses include decreased drug 
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efficacy, generation of cross-reactive antibodies, anaphylactic shock, and injection 
site reactions.1.2, 1.25,1.3
1.8   THESIS OBJECTIVES
 
! Pharmaceutical companies aim to develop safe, effective, and convenient 
delivery devices. The global market share of injectable drugs, representing about 
24% of all routes of drug administration, is growing 10% annually.1.16 Due to the 
conveniences offered as a means of storage prior to drug delivery to patients as well 
as compatibility with auto-injection devices that minimize handling procedures, 2.2 
billion prefilled syringes were sold in 2007.1.29 Silicone oil is a lubricant used in 
prefilled syringes to aid in plunger depression. Therapeutic proteins can be exposed 
to the silicone oil-water interface for the entire 18-24 shelf-life of a protein drug 
product. Currently, there is a dearth of published studies that aim to understand 
protein interactions with silicone oil contamination in pharmaceutical formulations. 
 Like previous studies, silicone oil emulsion was utilized in this study. In a 
typical 1 mL syringe, the maximum surface area of silicone oil that protein can 
interact with is roughly 10 cm2.1.24 In addition, for a 1 mL syringe lubricated with 
less than 1.5 mg of silicone oil, about 30-40 !g of silicone oil can be expelled in one 
drug dose.1.11-1.12 Industrially relevant silicone oil concentrations and surface areas 
cannot be analyzed using conventional techniques. To overcome this, a silicone oil 
emulsion with a suitable concentration and total surface area was prepared in-
house to be able to qualitatively and quantitatively assess protein-silicone oil 
interactions.
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 The overall goal of this work was to assess humanized monoclonal antibody 
interactions with silicone oil emulsion in the presence of 5 common pharmaceutical 
formulation excipients: Sodium chloride, sucrose, Tween® 20, Tween® 80, and 
poloxamer 188. In Chapter 2, it will be shown that human monoclonal antibodies 
adsorb to the silicone oil-water interface, may undergo conformational changes once 
adsorbed, and reduce the colloidal stability of silicone oil emulsion in formulations 
containing different excipients. In Chapter 3, the detection of protein adsorption 
and assessment of colloidal stability will be verified using a complementary 
technique. In Chapter 4, the competitive adsorption of protein and surfactant to this 
interface will be assessed. In addition, the formation of a protein-surfactant complex 
will be considered. Lastly, in Chapter 5, final conclusions will be summarized and 
future recommendations will be proposed.
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CHAPTER 2: EXCIPIENT EFFECTS OF HUMANIZED 
MONOCLONAL ANTIBODY INTERACTIONS WITH SILICONE OIL 
EMULSION
2.1   INTRODUCTION
 Therapeutic proteins are a growing class of drug products. A convenient 
strategy to deliver these drugs to patients is to administer them in a liquid 
formulation using prefilled glass syringes. In order to provide smooth plunger action 
and enhance compatibility with autoinjector devices, glass syringes typically must 
be lubricated by application of silicone oil to the syringe barrels. Because prefilled 
syringes act as both the delivery device and as a storage container, proteins 
formulated in prefilled syringes may be exposed to the silicone oil-water interface 
for the entire 18-24 month shelf-life.
Silicone oil contamination in insulin formulations was first documented twenty-
five years ago in reports that found that contamination up to 0.25 mg/mL of silicone 
oil in a 10 mL insulin vial was possible when a standard filling procedure for 
siliconized syringes was followed.2.9,2.10 More recently, several studies have been 
conducted to assess the behavior of proteins exposed to silicone oil. Jones et al. 
showed that silicone oil emulsions induced aggregation of ribonuclease A, lysozyme, 
bovine serum albumin, and concanavalin A.2.30 Similarly, Thirumangalathu et al. 
found that an IgG1 antibody aggregated in the presence of silicone oil emulsion 
when agitated.2.49 Ludwig et al. examined the effects of adsorption of BSA, 
lysozyme, abatacept, and trastuzumab to the silicone oil-water interface by 
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assessing the kinetic stability of silicone oil emulsions in the presence of 
excipients.2.33 In a comparability study, Lubiniecke et al. observed that a monoclonal 
antibody drug product exhibited greater levels of particles >10 µm, particles >25 
µm, and turbidity levels after storage in prefilled glass syringes as compared to 
storage in glass vials.2.32 Despite these efforts, the interaction of proteins with the 
silicone oil-water interface still remains poorly understood. 
In this work, we examined the adsorption of three human IgG1 monoclonal 
antibodies to the surfaces of silicone oil microdroplets in the presence of various 
excipients. In order to better resolve effects of silicone oil-water interfaces, an 
“accelerated” approach was chosen wherein proteins were exposed to silicone oil 
microdroplets in emulsions that presented roughly 100 to 1000 times the interfacial 
area to which proteins may be exposed within a prefilled syringe.  
Protein-silicone oil interactions were assessed in the presence of three common 
pharmaceutical formulation excipients: sodium chloride, sucrose, and Tween® 20. 
Sodium chloride increases the ionic strength in solution, which serves to reduce 
electrostatic interactions via charge shielding.2.7,2.28 Sucrose is a preferentially 
excluded co-solute that increases native protein conformational stability.2.48 Lastly, 
Tween® 20 is a surfactant that is anticipated to compete with proteins for 
adsorption sites at silicone oil-water interfaces.2.17,2.33-2.34 The goals of this work 
were to compare the behavior of three humanized monoclonal antibodies at the 
silicone oil-water interface, to determine whether silicone oil emulsion induces 
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homogeneous protein aggregation in solution, and to observe how different 
formulation excipients affect the colloidal stability of silicone oil emulsions.
2.2   MATERIALS AND METHODS
2.2.1   Proteins
 Three recombinant humanized monoclonal antibodies (referred to as humAb 
1, humAb 2, and humAb 3; these are the same antibodies whose adsorption 
behavior on glass microparticle surfaces was described previously2.26 were 
manufactured and provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland). 
humAb 1 and humAb 2 are humanized IgG from Chinese hamster ovary (CHO) cells 
and humAb 3 is humanized IgG from mouse cells. Each humAb is glycosylated. 
humAb 1 and humAb 2 were provided as frozen liquid formations of 89.1 mg/mL 
and 10.26 mg/mL, respectively, and stored at -80°C. humAb 3 was provided as a 
liquid formulation of 10.30 mg/mL and stored at 2-8°C. humAb 1, humAb 2, and 
humAb 3 were formulated in 20 mM L-histidine at pH 5.5, 20 mM L-histidine/
histdine-HCl at pH 6.0 containing 240 mM trehalose and 0.02% (w/v) Tween® 20, 
and 25 mM sodium acetate at pH 6.0 containing 125 mM sodium chloride, 
respectively. Additional information about each humAb is summarized in Table 2.1. 
2.2.2   Buffer Conditions
 Each humAb was dialyzed into 10 mM L-histidine at pH 6.0 containing 0.01% 
(w/v) sodium azide (hereafter denoted as “buffer”) using 10,000 MWCO Pierce Slide-
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A-Lyzer cassettes (Thermo Scientific, Rockford, IL). Using the appropriate 
extinction coefficient at 280 nm (see Table 2.1), protein concentrations were 
determined using a PerkinElmer Lambda 35 spectrophotometer (Wellesley, MA). 
The final concentration of protein in the stock solutions was adjusted to 5 mg/mL 
after dilution using buffer. Three excipient conditions were studied. These buffers 
contained 140 mM sodium chloride, 240 mM sucrose, or 0.03% (w/v) Tween® 20. All 
buffers were prepared using distilled deionized water and filtered using 0.22 µm 
pore-size filters (Millipore Corp., Billerica, MA). All chemicals used were reagent 
grade or higher quality.
2.2.3   Preparation of Silicone Oil Emulsion
 0.5-1.0% (v/v) silicone oil in water emulsions of medical grade 1000 cSt 
silicone oil (Dow Corning 360, Midland, MI) were prepared using a combination of 
mechanical mixing and high-pressure homogenization.2.33 A 100 mL suspension of 
5% (v/v) silicone oil in water was prepared by mixing silicone oil and water in a 
stainless steel cylinder at room temperature using a 20 mm shaft rotor/stator (The 
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____________________________________________________________________
  Molecular Weight (Da)   Extinction Coefficient Isoelectric Point 
                                                                at 280 nm (cm2/mg)               (Calculated)
____________________________________________________________________________
humAb 1          146,243            1.40                              9.0-10.0
humAb 2          145,996            1.49                     8.8-8.9
humAb 3          152,942            1.57                                  9.3
__________________________________________________________________
TABLE 2.1. Summary of some physical properties of each humAb
VirTis Co., Warminster, PA, Virtisshear Mechanical Homogenizer) for 15 minutes at 
5000 rpm. Immediately following mixing, the suspension was passed eight times 
through a high-pressure homogenizer (Avestin Inc., Ottowa, Ontario, Canada, 
Emulsiflex C5 Homogenizer) operating such that the pressure oscillated from 20-40 
kpsi. The final silicone oil emulsion was collected and stored in a 125 mL glass 
bottle. The difference between the initial and final silicone oil concentrations in 
emulsion was due to phase separation in the sample chamber prior to passage 
through the homogenizer.
2.2.4   Concentration of Silicone Oil in Emulsion
 The concentration of silicone oil suspended in the emulsions was determined 
using a combination of liquid-liquid extraction and infrared absorbance.2.33 A 1 mL 
aliquot of a 1:1 mixture of silicone oil emulsion and 0.5 M sodium chloride was 
added to 1 mL of n-hexane in a glass test tube. This mixture was mixed for 1 minute 
by vortexing and centrifuged at 1500g for 1 hour. The efficiency of extraction of 
silicone oil from water to n-hexane was improved by increasing the ionic strength of 
the aqueous phase (data not shown). Silicone oil has a characteristic absorbance at 
1260 cm-1 due to its Si-CH3 moieties.2.23 The infrared absorbance at 1260 cm-1 of 
silicone oil in n-hexane was measured using a Bomem MB154S (Quebec, QC, 
Canada) Fourier Transform Infrared (FT-IR) Spectrometer equipped with a Pike 
MIRacle™ (Madison, WI) attenuated total reflection sampling accessory containing 
a ZnSe crystal plate. The area of the peak at 1260 cm-1 was determined by 
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integrating the signal from 1245 cm-1 to 1275 cm-1. In order to determine the 
concentration of silicone oil in n-hexane from the area under the peak at 1260 cm-1, 
a standard curve was constructed. The area under the peak at 1260 cm-1 (y-axis) for 
known concentrations of silicone oil in n-hexane (x-axis) was plotted and fitted to 
the line y = 0.036x with R2 = 0.99 (Figure 2.1).
2.2.5   Particle Size Distribution of Silicone Oil Emulsion
 The particle size distribution of silicone oil droplets in emulsion was 
measured by laser diffraction analysis using a Beckman Coulter LS230 (Fullerton, 
CA). Scattering of silicone oil droplets assumed to be spheres was assessed using a 
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FIGURE 2.1. Standard curve showing the area of the peak at 1260 cm-1 as a 
function of mass concentration of silicone oil in n-hexane. The area of the peak at 
1260 cm-1 was determined from 1245 cm-1 to 1275 cm-1. This area was determined 
for silicone oil concentrations of 12.5, 6.25, 3.13, 1.56, 0.781, 0.391, 0.195, 0.0977 
mg/mL in n-hexane. The dotted line is a linear fit of the data. The equation of 
this line is y = 0.036x with an R2 value of 0.99. Data represents the arithmetic 
mean of three replicate samples. Error bars represent the standard error of the 
mean.
refractive index of silicone oil of 1.4046 provided by the manufacturer.2.55 The 
particle size distributions obtained were reported as a number or surface area 
percent versus particle diameter.
The total surface area of silicone oil in emulsion was determined from the 
particle size distribution obtained from the aforementioned analysis. The total 
number of particles per volume analyzed, N, was determined from mass balance 
according to Equation 1.         
where b is the number of bins describing the size distribution, ri is the radius of a 
silicone oil droplet in bin i, ni is the number percent in bin i, and V is the volume of 
silicone oil analyzed determined using the mass concentration of silicone oil in 
emulsion and a density of silicone oil of 0.972 g/mL (supplied by the 
manufacturer).2.55 The total number of particles per volume analyzed was typically 
on the order of 1011 droplets. Using this value, the surface area of particles in each 
bin was calculated and summed over all bins to yield the total surface area of 
silicone oil droplets in emulsion per volume of solution.
2.2.6   Silicone Oil-Induced humAb Loss from Solution  
 Samples were prepared by mixing silicone oil emulsion, 2 mg/mL stock 
humAb solution, and 6X buffer (in that order) in 15 mL polypropylene falcon tubes. 
Control samples containing water instead of silicone oil emulsion were also 
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(1)
prepared. The final humAb concentration in each sample was 0.2 mg/mL in buffer. 
Samples and control samples were incubated statically at room temperature (23ºC ± 
2ºC) for 30 minutes, 3 days, 1 week, 2 weeks, or 1 month. After each incubation 
period, 0.35 mL of sample and control were centrifuged at 18,000g for 15 minutes to 
separate silicone oil and protein adsorbed to silicone oil droplets from the aqueous 
supernate. The absorbance of protein at 280 nm in the supernate was measured 
using size exclusion high-performance liquid chromatography (SE-HPLC). SE-
HPLC analysis was conducted using a Beckman Coulter System Gold equipped with 
126 pump (Beckman Coulter Inc., Fullerton, CA), a Waters 717 Plus autosampler 
(Waters Corp., Milford, MA), and 168 UV detector (Beckman Coulter Inc., Fullerton, 
CA). Studies were conducted using a TSK-GEL G3000SWXL column (TOSOH 
Biosciences, Montgomeryville, PA). The mobile phase was a 0.2 M potassium 
phosphate buffer at pH 7.0 containing 0.25 M KCl and 0.01% (w/v) sodium azide 
that ran at a flow rate of 0.5 mL/min. 75 µL of sample was injected per run. The 
absorbance of eluate from the column was used to determine the mass of humAb 
eluted using the appropriate extinction coefficient (see Table 2.1). To determine the 
mass of humAb lost from solution, the mass of humAb eluted from samples 
containing silicone oil emulsion was subtracted from the mass of humAb eluted 
from samples containing no silicone oil. These values were normalized by the 
dividing by the initial silicone oil surface area per volume of the emulsion.
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2.2.7   humAb Conformation at the Silicone Oil-Water Interface 
 Tertiary structure of humAb molecules adsorbed to silicone oil-water 
interfaces was probed using tryptophan fluorescence quenching. Tryptophan 
residues of adsorbed protein were excited at 295 nm using an SLM-Aminco 
Spectrofluorometer (SLM-Aminco, Urbana, Il) in front-face geometry using a 
custom-built cuvette holder rotated 53° from the excitation beam. Samples were 
prepared by mixing 9 mL of silicone oil emulsion with appropriate amounts of 5 mg/
mL stock humAb solution and 4X buffer (in that order) in 15 mL polypropylene 
falcon tubes such that the amount of protein not adsorbed to the silicone oil-water 
interface was minimized. Samples were incubated statically for at least 2 hours at 
room temperature (23ºC ± 2ºC). Freshly prepared 7.6 M acrylamide solution was 
used as a quenching agent. Spectra were recorded after each addition of acrylamide. 
A total of four aliquots of acrylamide were added to each sample until the final 
acrylamide concentration was approximately 0.25 M. Fluorescence intensities were 
recorded from 300 nm to 380 nm at a scan rate of 0.95 nm/s.  Spectra were recorded 
at room temperature (23ºC ± 2ºC). Tryptophan emission fluorescence was monitored 
at 328 nm. Raw fluorescence intensities were corrected for dilution after addition of 
each aliquot of acrylamide and the inner-filter effect resulting from absorption of 
acrylamide at 295 nm. The relationship between corrected fluorescence intensity 
values and acrylamide concentration was assessed using the Stern-Volmer 
equation2.18-2.19:
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(2)
                                  
where F0 is the initial fluorescence intensity, F is the fluorescence intensity at a 
particular quencher concentration, [Q] is the quencher concentration, and KSV is the 
Stern-Volmer constant. This fit was linear (R2 values ranging from 0.992 to 0.998) 
through five points for acrylamide concentrations ranging from 0 to 0.25 M. Blank 
corrections were made by subtracting the spectra of corresponding humAb-free 
samples.
2.2.8   Colloidal Stability
 The colloidal stability of humAbs and silicone oil emulsions were assessed 
using laser Doppler velocimetry. A Malvern Zetasizer Nano ZS (Worcestershire, 
United Kingdom) was used to measure the electrophoretic mobility of protein and 
silicone oil dispersions in an applied electric field. The zeta potential was calculated 
from Henry’s equation using the Smoluchoski approximation valid at ionic 
strengths greater than 1 mM2.20: 
(3)
µe is the electrophoretic mobility, $ is the dielectric constant of the solution, ks = 1.5 
is a model-based constant, ) is the solution viscosity, and * is the zeta potential. The 
viscosity of solution was assumed to be that of water for all buffer conditions except 
when the formulation contained sucrose. Viscosities for sucrose solutions were 
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obtained from ISCO tables.2.25 Samples were prepared by mixing silicone oil 
emulsion, 2 mg/mL protein, and 6X buffer (in that order) in 1.5 mL polypropylene 
microcentrifuge tubes. The final protein concentration in each sample was 0.2 mg/
mL in buffer. Samples were incubated statically at room temperature (23ºC ± 2ºC) 
for 30 minutes, 3 days, 1 week, 2 weeks, or 1 month. After incubation, a 20:1 
dilution of silicone oil emulsion in the appropriate buffer was prepared and 0.8 mL 
of diluted sample was analyzed using a disposable capillary zeta potential cell 
equipped with gold electrodes (Malvern Instruments Ltd., Worcestershire, United 
Kingdom).
To investigate the effect of electrostatics in particle interactions, Derjaguin-
Landau-Verwey-Overbeek (DLVO) theory was invoked. The total interaction 
potential between two spheres of unequal radii encompassing both van der Waals 
attractive forces and electrostatic double layer repulsive forces is given as2.6,2.27:
(4)
where $ is the dielectric constant of the dispersant phase, r is the particle radius, + 
is the surface potential, & is the inverse Debye length, D is the interparticle 
separation distance, and AH is the Hamaker constant which is approximately 5 kT 
for proteins.2.37 For the analysis in this study, the zeta potential was substituted for 
the surface potential. 
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2.2.9   Fluorescence-Activated Particle Analysis
 humAbs were fluorescently labeled with Alexa Fluor® 647 (Invitrogen Corp., 
Carlsbad, CA). Alexa Fluor® 647 is a bright and photostable dye with absorption 
and fluorescence maxima of approximately 650 nm and 668 nm, respectively.2.56 In 
addition, Alexa Fluor® 647 is pH insensitive between 4 and 10 and resistant to 
quenching at high degrees of substitution.2.56 Each humAb was dialyzed into 
phosphate-buffered saline (PBS) and diluted to 2 mg/mL. A 0.5 mL aliquot of 2 mg/
mL humAb solution in PBS was incubated with Alexa Fluor® 647 dye for 1 hour 
with gentle stirring. Alexa Fluor® 647 dye has a succinimidyl ester moiety that 
reacts efficiently with primary amines of a protein.2.56 For this reason, conjugation 
cannot proceed in buffer containing L-histidine. Immediately after the labeling 
reaction, labeled humAb was separated from unreacted dye molecules using a 
30,000 MW size-exclusion resin (Invitrogen Corp., Carlsbad, CA) in PBS at pH 7.2 
containing 2 mM sodium azide. The concentration of labeled humAb was 
determined using Equation 5:
                    
                  
!
(5) 
where A280 is the absorbance at 280 nm, A650 is the absorbance at 650 nm, $protein is 
the extinction coefficient at 280 nm (see Table 2.1), CF = 0.03 is a correction factor 
that accounts for the contribution of Alexa Fluor® 647 to the absorbance at 280 nm, 
and DF is a dilution factor. The degree of labeling was determined using Equation 6:
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(6)
where $dye = 239,000 cm-1 M-1 is the molar extinction coefficient of Alexa Fluor® 647 
dye. The degree of labeling for humAb 1, humAb 2, and humAb 3 was 6.96 ± 0.01, 
7.18 ± 0.01, and 7.98 ± 0.01 moles of dye per mole of protein, respectively. Prior to 
use, labeled humAb was dialyzed into 10 mM L-histidine at pH 6.0 containing 
0.01% (w/v) sodium azide and stored protected from ambient light.
Silicone oil was stained with 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-
diaza-s-indacene (BODIPY® 493/503).2.34 BODIPY® 493/503 was chosen because it 
is a nonpolar, electrically neutral molecule that is highly soluble in silicone oil.2.34 
This dye has absorption and fluorescence maxima of approximately 488 nm and 515 
nm, respectively.2.57 BODIPY® 493/503 was dissolved in 2 mL of dimethylsulfoxide 
(DMSO) at a concentration of 2.5 mg/mL. A 10 mL aliquot of silicone oil was 
dissolved in 40 mL of dichloromethane (DCM). After complete dissolution of 
BODIPY® 493/503 and silicone oil into their respective solvents, 800 $L of 
BODIPY® 493/503-DMSO solution was added to the silicone oil-DCM solution and 
mixed for 1 hour at room temperature. Immediately following mixing, DMSO and 
DCM were removed using a Laborota 4000eco rotary evaporator (Heidolph- 
Brinkmann, Elk Grove Village, IL). About 80% percent of labeled silicone oil was 
recovered. 
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Emulsions of labeled silicone oil were created as described above. Samples were 
prepared by mixing labeled silicone oil emulsion, 0.1 mg/mL labeled protein, and 6X 
buffer (in that order) in 2 mL polypropylene microcentrifuge tubes. The final protein 
concentration in each sample was 0.01 mg/mL in buffer. Samples were incubated 
statically at room temperature (23ºC ± 2ºC) for 30 minutes, 3 days, 1 week, 2 weeks, 
or 1 month. After incubation, 200 µL of sample was analyzed using a BD 
FACSCaliburTM instrument (Becton Dickinson and Co. Biosciences, San Jose, CA) 
equipped with a 488 nm blue argon laser, 635 nm red diode laser, four fluorescence 
detectors (FL1 530/30, FL2 585/42, FL3 670LP, and FL4 661/16), and 488 nm 
forward and 90° side light scattering detectors. The fluorescence intensities of Alexa 
Fluor® 647 and BODIPY® 493/503 for 30,000 particles were plotted. The data were 
fit to Equation 7:
where IAF-647 is the fluorescence intensity of protein labeled with Alexa Fluor® 647, 
IBODIPY is the fluorescence intensity of silicone oil droplets labeled with BODIPY® 
493/503, A(,) is a constant, and v is a scaling exponent. Sheath fluid matching the 
formulation buffer was used to dilute samples.
2.2.10   Light Microscopy
 Silicone oil emulsion stability in the presence of humAbs was assessed 
visually using light microscopy. Droplets were imaged at 400X using an Eclipse 
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(7)
TE300 inverted optical microscope (Nikon Instruments Inc., Melville, NY) with a 
SPOT™ RT-KE CCD camera (Sterling Heights, MI). Samples were prepared by 
mixing silicone oil emulsion, 2 mg/mL protein, and 6X buffer (in that order) in 2 mL 
polypropylene microcentrifuge tubes. The final protein concentration in each sample 
was 0.2 mg/mL in buffer. Samples were incubated statically at room temperature 
(23ºC ± 2ºC) for 1 month.
2.2.11   Statistical Analysis 
 In this work, averaged values are reported with standard errors about the 
mean. Also, student’s t-test was used obtain a p-value that was used to assess 
statistically significant differences observed between data sets. A p-value less than 
0.05 indicated that data sets were statistically different.
2.3   RESULTS
2.3.1   Characterization of Silicone Oil Emulsion
 From analysis of the peak at 1260 cm-1 using ATR-FTIR, the mass 
concentration of silicone oil in the emulsion was found to be 6.90 ± 0.82 mg/mL, or 
0.71 ± 0.08 % (v/v). 
Silicone oil emulsion particle size distributions were assessed as both number- 
and surface area-weighted distributions (Figure 2.2). The majority of silicone oil 
droplets were about 0.1 µm in diameter (Figure 2.2A). A small minority of larger 
droplets were present as was evident from the surface area-weighted particle size 
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distribution. This distribution exhibited a bimodal distribution with maxima at 
roughly 0.1 µm and 1.7 µm (Figure 2.2B). Analysis of these particle size 
distributions revealed that 1 mL of silicone oil emulsion had a total surface area of 
330 ± 40 cm2. 
2.3.2   Silicone Oil-Induced humAb Loss from Solution
 After 1 month of static incubation at room temperature, SE-HPLC analysis of 
samples containing humAbs 1-3 and silicone oil emulsion provided no evidence that 
soluble protein aggregates (< 1,000 kDa) formed as a result of protein-silicone oil 
interactions under static conditions. No aggregate peaks were observed in any of the 
chromatograms obtained (Figure 2.3). Accordingly, after a rapid initial loss of 
protein from solution due to adsorption to silicone oil droplets, there was no 
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FIGURE 2.2. Representative particle size distributions of silicone oil emulsion 
prepared in water. Droplet diameters are grouped into bins and represented as a 
percent of the total number of droplets analyzed. (A) Percent number particle size 
distribution. (B) Percent surface area particle size distribution.
noticeable decrease in the mass of monomeric protein with time. In addition, there 
was no visible evidence of the formation of insoluble protein aggregates. In the 
absence of formulation excipients, silicone oil-induced protein loss from solution 
varied for each humAb such that humAb 1 < humAb 3 < humAb 2 (Figure 2.4). 
These differences were statistically significant (p < 0.05). Although the amount of 
protein lost from solution varied for the three humAbs investigated, the same trend 
in the presence of different formulation excipients was exhibited. For formulations 
containing sodium chloride, the silicone oil-induced protein loss from solution was 
greater than for formulations containing no excipients. This difference was 
statistically significant for humAb 1 and humAb 3 (p < 0.05) but not statistically 
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FIGURE 2.3. Representative chromatograms from SE-HPLC. A control that was not 
incubated with silicone oil emulsion is represented by the solid line. A sample that 
was incubated with silicone oil emulsion is represented by the dashed line. There is 
a peak at roughly 17 minutes that corresponds to native humAb monomers. The 
formation of small homogeneous protein aggregates would appear at times before 
the monomer peak.
significant for humAb 2 (p > 0.05). For formulations containing sucrose, differences 
from values obtained for formulations containing no excipients were not statistically 
significant for humAbs 1-3 (p > 0.05). Lastly, for formulations containing Tween® 
20, silicone oil-induced protein loss from solution was less than that of formulations 
containing no excipients. These differences were statistically significant for humAbs 
1-3 (p < 0.05).
2.3.3   humAb Conformation at the Silicone Oil-Water Interface
 Over the range of acrylamide concentrations tested, Stern-Volmer plots for 
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FIGURE 2.4. Loss of protein from solution after incubation of humAbs with silicone 
oil emulsion for 72 hours. Data for humAb 1, humAb 2, and humAb 3  are labeled 
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humAb 1 humAb 2 humAb 3
 10 mM L-histidine at pH 6.0 containing 0.01% (w/v) sodium 
























humAb 1 humAb 2 humAb 3
 10 mM L-histidine at pH 6.0 containing 0.01% 
(w/v) sodium azide and 0.03% (w/v) Tween® 20. Data represents the 
arithmetic mean of three replicate samples. Error bars represent the 
standard error of the mean.
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fluorescence quenching revealed that protein adsorbed to the silicone oil-water 
interface had increased tryptophan exposure to acrylamide, perhaps indicative of 
conformationally perturbed protein (Figure 2.6). In formulations containing humAb 
1 and humAb 2, differences between Stern-Volmer constants of adsorbed protein 
and unfolded protein were not statistically significant (p > 0.05). However, this 
difference for humAb 3 was statistically significant (p < 0.05). For each humAb, 
there was not a statistically significant difference between formulations containing 
sodium chloride or sucrose and formulations containing no excipients (p > 0.05). 
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FIGURE 2.5. Representative Stern-Volmer plot obtained from front-face fluorescence 
quenching. These plots were linear with an R2 of ca. 0.99. Data represents the 
arithmetic mean of three replicate samples. Error bars  represent the standard 



















































FIGURE 2.6. Measured Stern-Volmer constants after incubation of humAbs  w i t h 
silicone oil emulsion for at least 2 hours. (A) humAb 1. (B) humAb 2. (C) humAb 3. 
Data for each protein in 10 mM L-histidine at pH 6.0 containing 0.01% (w/v) 
sodium azide in the presence of no excipients, 140 mM sodium  chloride, or 240 mM 
sucrose are labeled accordingly. For each protein, there are three bars representing 
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humAb 1 humAb 2 humAb 3
 unfolded protein in 9.5 M urea. Data represents the arithmetic mean of three 
replicate samples. Error bars represent the standard error of the mean.
2.3.4   Colloidal Stability of humAbs
 The zeta potentials of native humAbs 1-3 were statistically different from one 
another (p < 0.05). In addition, the zeta potentials of humAbs 1-3 were dependent 
on the presence of excipients (Figure 2.7). In formulations containing sodium 
chloride, the zeta potentials of humAb 1 and 3 were statistically different than 
those in formulations containing no excipients (p < 0.05). However, this difference 
was not statistically significant for humAb 2 formulations (p > 0.05). In 
formulations containing sucrose, the zeta potential of each humAb was not 
statistically different than in formulations containing no excipients (p > 0.05). 
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FIGURE 2.7. Zeta potential of native humAbs. Data for humAb 1, humAb 2,  a n d 
humAb 3 are labeled accordingly. For each protein, there are four bars  representing 
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10 mM L-histidine at pH 6.0 containing 0.01% (w/v) sodium azide 
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 10 mM L-histidine at pH 6.0 containing 0.01% (w/v) 
























humAb 1 humAb 2 humAb 3
 10 mM L-histidine at pH 6.0 containing 0.01% 
(w/v) sodium azide and 0.03% (w/v) Tween® 20. Data represents the arithmetic 
mean of three replicate samples. Error bars represent the standard error of the 
mean.
Lastly, in formulations containing Tween® 20, the zeta potential of humAb 1 was 
statistically different compared to formulations containing no excipients (p < 0.05), 
but the difference was not significant for humAb 2 and humAb 3 (p > 0.05).
2.3.5   Colloidal Stability of Silicone Oil Emulsion
 The average zeta potential of silicone oil droplets in water was -73.3 ± 2.6 mV 
and did not change significantly (p > 0.05) over a one-month incubation period 
(Figure 2.8). The zeta potential of humAb-free silicone oil droplets in emulsion was 
dependent on the presence of excipients (Figure 2.9A). In formulations containing 
no excipients or sucrose, there appeared to be a slight decrease in the zeta potential 
to more negative values at longer incubation times. However, this difference was 
not statistically significant (p > 0.05). Conversely, in formulations containing 
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FIGURE 2.8. Zeta potential of silicone oil in emulsion in water plotted versus 
incubation time. Data represents the arithmetic mean of three replicate samples. 


















sodium chloride, the zeta potential increased with increasing incubation time, 
approaching a value of zero after 1 month. Lastly, formulations containing Tween® 
20, the average zeta potential over a 1 month period was -8.75 ± 0.83 mV.
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FIGURE 2.9. Zeta potential of humAb-coated silicone oil droplets plotted versus 
incubation time. (A) No protein. (B) humAb 1. (C) humAb 2. (D) humAb 3. For each 
case, there are four data sets representing different excipient conditions in 10 mM L-
histidine at pH 6.0 containing 0.01% (w/v) sodium azide:  No excipients, O  140 mM 
sodium chloride, ! 240 mM  sucrose, ♢ 0.03% (w/v) Tween ® 20. Symbols represent 
the arithmetic mean of three replicate samples. Error bars represent the standard 
error of the mean.
 Immediately following humAb adsorption to the silicone oil-water interface, 
the zeta potential of silicone oil droplets in emulsion changed drastically for all 
formulations (Figure 2.9B-D). In formulations containing no excipients, there was a 
reversal in the sign of the measured zeta potentials from negative to positive. 
Differences in these values for formulations containing humAbs 1-3 were 
statistically significant (p < 0.05). Over a period of 1 month, the zeta potential of 
silicone oil droplets decreased with time. This decrease was statistically significant 
for each humAb formulation (p < 0.05). In formulations containing sodium chloride 
or sucrose, the measured zeta potential was significantly lower than in formulations 
containing no excipients with no clear change with incubation time. Similarly, the 
zeta potential of silicone oil droplets in formulations containing Tween® 20 were 
lower than in formulations containing no excipients. However, there was a decrease 
in the zeta potential of silicone oil droplets with time such that after 1 month of 
incubation the zeta potential approached that of humAb-free solutions. The 
difference between the zeta potentials of silicone oil droplets formulated with 
humAbs 1-3 and Tween® 20 incubated for 1 month and the same formulations 
incubated without humAbs 1-3 was not statistically significant (p > 0.05).     
2.3.6   Fluorescence-Activated Particle Analysis
 Fluorescence-activated particle analysis can differentiate between protein 
particles without silicone oil and protein adsorbed to the surface of silicone 
microdroplets.2.34 In the current study, there was no evidence that protein 
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aggregates > 0.2 !m formed as a result of protein-silicone oil interactions (Figure 
2.10). Such protein-only particulates, had they been present, would have appeared 
as a population in the upper left quadrant in Figure 2.10.
After 30 minutes of incubation, the scaling exponent (Figure 2.11) ranged from 
0.60 to 0.68 in all formulations examined. This value increased with incubation time 
over the course of a one-month storage period, with the largest incremental change 
occurring between 30 minutes and 72 hours. This change was greatest in 
formulations containing sodium chloride.  In formulations containing no excipients 
or sucrose, the largest incremental changes during this period were similar. After 1 
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FIGURE 2.10. Representative plot of the fluorescence intensity of humAb labeled 
with Alexa Fluor® 647 versus the fluorescence intensity of silicone oil emulsion 
labeled with BODIPY® 493/503. Each of the 30,000 dots on the plot represents one 
silicone oil droplet with adsorbed humAb. The vertical axis reflects fluorescence due 
to Alexa Fluor® 647; the horizontal axis corresponds to fluorescence from silicone oil 
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FIGURE 2.11. Scaling exponents determined from fluorescence-activated particle 
analysis plotted versus incubation time. (A) humAb 1. (B) humAb 2. (C) humAb 3. 
For each protein, there are three data sets representing different excipient 
conditions in 10 mM L-histidine at pH 6.0 containing 0.01% (w/v) sodium azide:  
No excipients, O  140 mM sodium chloride, ! 240  mM sucrose. Symbols represent 
the arithmetic mean of three replicate samples. Error bars represent the standard 

















































month of incubation, the scaling exponent was statistically different than the value 
determined after 30 minutes (p < 0.05) in all formulations. This experiment was 
also performed with humAb formulations containing Tween® 20. However, due to 
the low levels of protein adsorbed to silicone oil droplets under these conditions, 
Alexa Fluor® 647 fluorescence was below meaningful detection limits (Figure 
2.12).  
 Histograms of BODIPY® 493/503 and Alexa Fluor® 647 fluorescence 
intensities were plotted for each time point (Figure 2.13). These histograms serve as 
particle size distributions. It was observed that the fraction of particles with 
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FIGURE 2.12. Representative plot of the fluorescence intensity of humAb labeled 
with Alexa Fluor® 647 versus the fluorescence intensity of silicone oil emulsion 
labeled with BODIPY® 493/503 for formulations containing 0.03%  (w/v) Tween® 20. 
Each of the 30,000 dots on the plot represents one silicone oil droplet with adsorbed 
humAb. The vertical axis reflects fluorescence due to Alexa Fluor® 647; the 
horizontal axis corresponds to fluorescence from silicone oil stained with BODIPY® 
493/503.
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FIGURE 2.13. Fluorescence intensity histograms for 30,000 particles are presented 
for silicone oil emulsion labeled with BODPIY® 493/503 (A, C, E) and humAbs 
labeled with Alexa Fluor® 647 (B, D, F). Blue, green, orange, purple, and red 
histograms correspond to 30 minutes, 3 days, 1 week, 2 weeks, and 1 month 
incubation times, respectively.
fluorescence intensities between 10 and 100 increased with increasing incubation 
time in formulations containing no excipients or sucrose. In formulations containing 
sodium chloride, there was an increase in fraction of particles with fluorescence 
intensities between 100 and 1000 with incubation time. These observations were 
consistent in formulations containing humAbs 1-3. 
2.3.7   Light Microscopy to Inspect Silicone Oil Droplet Flocculation
 Light microscope images of silicone oil emulsion incubated for 1 month with 
humAb 1-3 revealed that bridging flocculation of droplets had occurred (Figure 
2.14). In formulations containing no excipients or sucrose, there were relatively few, 
small flocs formed. Identification of flocs was even more difficult in formulations 
containing Tween® 20. Conversely, in formulations containing sodium chloride, 
large flocs were easily observed.
2.4   DISCUSSION
2.4.1   Characterization of Stock Silicone Oil Emulsion 
 Plunger depression in 1 mL prefilled syringes lubricated with silicone oil can 
expel 30-40 ppm of dilute silicone oil emulsion into solution.2.9,2.10 The 0.5-1.0% 
silicone oil emulsion used in this study was roughly 100X the concentration of 
silicone oil emulsion that can be expelled by a typical 1 mL prefilled syringe, 
allowing the use of conventional analytical techniques to monitor processes like 
adsorption and aggregation in an “accelerated” approach.          
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2.4.2   Silicone Oil-Induced humAb Loss from Solution
 Since there was no observable evidence that silicone oil-induced protein loss 
from solution could have resulted from protein aggregation, it is reasonable to 
assume that the values obtained reflect the amount of protein adsorbed to the 
silicone oil-water interface. These surface loading values ranged from 0.1-2.0 mg/m2 









FIGURE 2.14. Visual Evidence of bridging flocculation of humAb-coated silicone oil 
droplets obtained from light microscopy. Samples are formulated with different 
excipients in 10 mM L-histidine at pH 6.0 containing 0.01%  (w/v) sodium azide. (A) 
No excipients. (B) 140 mM sodium chloride. (C) 240 mM sucrose. (D) 0.03% (w/v) 
Tween® 20. Each image is at 400X  magnification and the scale bar represents a 
distance of 25 !m. 
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addition of sodium chloride resulted in increased protein adsorption to silicone oil, 
likely due to increased screening of charges that reduced protein-protein repulsive 
forces at the interface. Conversely, the data suggested that in the presence of 
Tween® 20, less protein adsorbed to silicone oil than in the absence of formulation 
excipients. Tween® 20 most likely competed with protein for adsorption sites at the 
interface.2.17,2.40 If this was the case, then the results showed that Tween® 20 
preferentially adsorbed to the silicone oil-water interface instead of humAb 1-3. 
However, in the presence of sucrose, there was seemingly no difference in surface 
coverage compared to formulations containing no excipients. This behavior was 
consistent for each humAb.
 This study used three humanized monoclonal antibodies with similar 
hydrodynamic radii, isoelectric points, and molecular weights (see Table 2.1). 
Interestingly, based on the silicone oil-induced protein loss from solution calculated 
in the absence of formulation excipients, the amount of each humAb that adsorbed 
varied. The amount that adsorbed was not limited by the amount of protein added, 
since roughly four times as much protein remained free in solution as adsorbed to 
silicone oil microdroplets. In all cases, the amount of protein adsorbed was less than 
the amount that could theoretically adsorb in a hexagonally close-packed monolayer 
(about 2.5 mg/m2)2.3, and the amount of protein adsorbed represented only about 
20% or less of the total protein in each sample.
There are several potential, non-exclusive explanations for why humAbs 1-3 
exhibit differences in adsorption to the silicone oil-water interface. First, humAbs 
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1-3 may adsorb to the interface in different preferential orientations. Second, 
nearest-neighbor interactions between humAbs 1-3 may differ. Third, differences in 
silicone oil-induced conformational changes at the interface may have resulted in 
different protein-silicone oil interfacial contact areas for humAbs 1-3. However, 
there is insufficient information at this time to determine which mechanism(s) are 
responsible for differences in silicone oil interactions between humAbs 1-3.
2.4.3   humAb Conformation at the Silicone Oil-Water Interface
 humAbs 1-3 have 9, 11, and 13 tryptophan residues, respectively. At distances 
less than about 3Å, acrylamide dynamically quenches tryptophan fluorescence 
emission.2.47 The Stern-Volmer constant reflects the accessibility of acrylamide to 
these residues in humAbs 1-3. Stern-Volmer constants showed that acrylamide 
accessibility to tryptophan was essentially equivalent for humAbs unfolded in urea 
or adsorbed at the silicone oil-water interface, and substantially greater than that 
for folded, native protein in solution. Addition of sucrose or sodium chloride to the 
formulation did not affect the value of the Stern-Volmer constant. Sodium chloride 
increased humAb packing at the silicone oil-water interface, but this did not 
influence tryptophan exposure to solvent. Sucrose is used to enhance the 
conformational stability of protein in solution through preferential hydration.2.48 
Stern-Volmer constants for humAbs 1-3 adsorbed to silicone oil/water interfaces 
were not affected by the addition of sucrose, suggesting that stabilization of 
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humAbs 1-3 in the bulk solution did not block the apparent change in conformation 
that lead to enhanced acrylamide accessibility to tryptophan residues.
Each of the three humAbs used in this work adsorbed to the silicone oil-water 
interface. Previous work with these same humAbs showed that these proteins also 
adsorbed to glass microparticles, with similar dependence of the surface loading 
values on formulation excipients.2.26 Behavior of proteins at the solid-liquid 
interface is expected to differ from their behavior at fluid-fluid interfaces.2.17 
Specifically, at fluid interfaces, proteins can penetrate into the non-aqueous phase 
and diffuse faster at the surface, and more orientational and conformational 
changes occur at fluid interfaces than at solid interfaces.2.17 Comparison of Stern-
Volmer constants for humAbs 1-3 adsorbed to silicone oil from the current work 
with previously reported Stern-Volmer constants for humAbs 1-3 adsorbed to 
glass2.26 suggests that humAbs 1-3 retain substantially native-like structure when 
adsorbed to glass but may unfold at the silicone oil-water interface. 
2.4.4   Colloidal Stability of humAbs     
 The zeta potentials of humAbs 1-3 were excipient-dependent. In formulations 
containing sodium chloride, zeta potentials were drastically reduced as result of 
increased charge shielding. Addition of sucrose had no effect on zeta potentials of 
humAbs1-3. Small decreases in zeta potential were seen in the presence of Tween® 
20. The reasons for these decreases are not clear.
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                56
 For humAbs 1-3, under all conditions, the measured zeta potentials of the 
proteins in the absence of silicone oil were less than 20 mV. These dispersions were 
colloidally unstable, but aggregation in the absence of silicone oil was not observed 
over the time period studied.       
             
2.4.5   Colloidal Stability of Silicone Oil Emulsion
 Silicone oil droplets in pure water were negatively charged. The reason that 
emulsions were negatively charged is currently unknown. One possibility is that 
hydroxide ions adsorb to the interface.2.35 Stock silicone oil emulsions were 
colloidally stable for at least 1 month at room temperature (see Figure 2.8). From 
Equation 4, the electrostatic energy barrier for droplet coalescence plotted in Figure 
2.15 was approximately 150 kT and 3500 kT for 0.1 µm and 2 µm droplets, 
respectively. 
 Upon adsorption of humAbs 1-3, silicone oil emulsions were colloidally 
destabilized for all formulations examined. In formulations containing sodium 
chloride, near-zero zeta potentials of silicone oil droplets were observed, likely the 
result of increased charge shielding.  Interestingly, the same effect was observed in 
formulations containing sucrose. The reason for this unexpected result is unknown. 
Lastly, in formulations containing Tween® 20, decreasing zeta potential values that 
approached those for humAb-free solutions suggested that surfactant preferentially 
adsorbed to the silicone oil-water interface, displacing adsorbed humAb.
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 For two droplets of unequal radii, the electrostatic activation energy barrier 
to flocculation was estimated using Equation 4. Figure 2.15 shows that this energy 
barrier is expected to increase with particle diameter. Each line represents the same 
incremental increase in the activation energy barrier to flocculation. For every 
formulation investigated excluding formulations containing sodium chloride, the 
Debye length was about 8.6 nm. At a zeta potential of 30 mV, each line represents 
an incremental increase of about 20 kT. For lower zeta potentials, the incremental 
change decreases whereas at higher zeta potentials it increases. However, at zeta 
potentials less than approximately 12 mV, the activation energy barrier to 
flocculation falls to zero. Similarly, in formulation buffer containing sodium 
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FIGURE 2.15. Representative contour plot illustrating the activation barrier to 
flocculation of two particles of different diameter. Colors range from blue to red 
representing the increase in the activation barrier from small to large  values. For 
particles with a zeta potential of 30 mV, each contour represents an increase of 
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chloride, where the Debye length was about 1.1 nm, there was no activation energy 
barrier to flocculation at the zeta potentials obtained in this work.
         
2.4.6   Fluorescence-Activated Particle Analysis
 The amount of humAb adsorbed to the silicone oil-water interface was 
proportional to the interfacial surface area present. For spherical droplets coated 
uniformly with protein, a log-log plot of the fluorescence intensities of BODIPY® 
493/503-labeled silicone oil and Alexa Fluor® 647-labeled humAb on the x- and y-
axis, respectively, should yield a slope equal to 2/3. This slope is equal to the scaling 
exponent presented in Equation 7. Indeed, after 30 minutes of incubation, 
fluorescence-activated particle analysis yielded values of the scaling exponent close 
to this value for each excipient condition for humAbs 1-3 (Figure 2.11). However, the 
scaling exponent value increased with incubation time, suggesting that bridging 
flocculation between droplets was occurring.
 To deduce whether bridging flocculation was occurring in solution, the 
particle size distributions in each formulation were assessed (Figure 2.13). In all 
formulations excluding formulations containing sodium chloride, it was found that 
the fraction of droplets with the highest fluorescence intensities ranging from 
100-1000 decreased with time. Under static conditions, it seems unlikely that large 
droplets would fragment into smaller droplets. Instead, from visual inspection, it 
seems more likely that these droplets collided and stuck to the container walls. 
Because this technique can detect particles > 0.2 !m, the observed increase in the 
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fraction of small particles with time can be attributed to the formation of flocs by 
bridging flocculation. Individual particles that were initially too small to be detected 
may have flocculated resulting in flocs large enough to be detected. In formulations 
containing sodium chloride, there was an increase in the fraction of particles at 
fluorescence intensities ranging from 100-1000. These results suggest that larger 
flocs formed in the presence of sodium chloride than in the other excipient 
conditions which implies that floc size is related to the solution ionic strength. 
Unfortunately, in formulations containing Tween® 20, due to low humAb surface 
coverages, this kind of analysis could not be conducted.
 humAb-coated silicone oil emulsions were colloidally unstable, and evidence 
suggests that bridging flocculation occurred in silicone oil emulsions. However, no 
protein aggregates were detected in using SE-HPLC or fluorescence-activated 
particle analysis. Silicone oil emulsions have been shown to phase separate under 
static conditions due to density differences between silicone oil and water (Figure 
2.16).2.33 Silicone oil is less dense than water to which it is suspended. As a result, 
silicone oil droplets rose in solution. As the local concentration of droplets at the top 
of the container increased, bridging flocculation occurred. Assuming diffusion-
limited growth, the rate of floc formation should be proportional to the square of the 
number concentration of droplets.2.24 As expected, increases in the scaling exponent 
indicated that bridging flocculation had occurred at the fastest rate between 30 
minutes and 3 days. After 1 month of incubation, this rate decreased because either 
the number concentration of droplets decreased appreciably and/or flocs formed 
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were so large that the electrostatic activation barrier to flocculation was too large 
for continued floc growth.
2.4.7   Light Microscopy to Inspect Silicone Oil Droplet Flocculation
 
 In accordance with Ludwig et al., silicone oil emulsion formulation with 
Tween® 20 did not seem to flocculate (Figure 2.14).2.33 In both the excipient-free 
formulation and formulations containing sucrose, one can see small flocs by light 
microscopy, whereas in formulations containing sodium chloride one can see large 
flocs. From visual inspection, the number concentration of droplets correlates 
inversely with the size of flocs formed. Conditions in which the largest flocs had 
formed had the lowest number concentration of silicone oil droplets whereas 
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A B.
FIGURE 2.16. Example illustrating the creaming of silicone oil emulsion after 
sufficient incubation time. (A) Prior to incubation. (B) After incubation.
conditions with much smaller flocs had a higher number concentration of silicone oil 
droplets.
We speculate that a similar flocculation phenomenon might be operative in 
some actual therapeutic protein formulations, where visible particles may 
sometimes appear over the course of the therapeutic protein’s shelf life. Small 
droplets of silicone oil, colloidally destabilized by adsorption of protein, may 
flocculate into larger, visible assemblies. The appearance of such visible particles 
may not reflect ongoing protein aggregation.   
2.5   CONCLUSION
 This study sought to identify if the presence of silicone oil in pharmaceutical 
formulations alone was enough to induce homogeneous humAb aggregation. From 
this study, it was not. It was found that humAbs adsorb to the silicone oil-water 
interface. Silicone oil droplets were colloidally destabilized by humAb adsorption 
and flocculated. Flocculation can result in the formation of visible particles (Figure 
2.17).  Visible particles and even sub-visible particles can result in lowered drug 
efficacy, unwanted immune responses, and shortened shelf-lives. Pharmaceutical 
companies strive to avoid these problems through stringent quality assurance and 
control protocols. According to USP <788>, a sterile injectable solution should be 
free of visual particulate matter.2.39 With that being said, formulations with visual 
particulates are likely to be discarded. Financially, this poses a serious problem that 
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needs to be avoided through continued research and development advances that 
aim to understand how protein therapeutics behave with respect to the container/
closure system, microparticle contaminants, or leachables under various stresses.
2.6   REFERENCES
2.1 Bam, N.B., Cleland, J.L., Yang, J., Manning, M.C., Carpenter, J.F., Kelley, 
  R.F., Randolph, T.W. (1998). “Tween Protects Recombinant Human Growth 
  Hormone Against Agitation-Induced Damage Via Hydrophobic Interactions.” 
  J Pharm Sci. 87: 1554-1559. 
2.2 Bee, J.S. (2009). “Front-Face Fluorescence Quenching and FRET Techniques 
  to Probe the Structure of a Protein Antigen Adsorbed to Vaccine Adjuvant. In 
  Effect of Interfaces and Shear on Therapeutic Protein Stability.” Ph.D. 
  Thesis: 237-254. 
2.3 Bee, J.S., Chiu, D., Sawicki, S., Stevenson, J.L., Chatterjee, K., Freund, E., 
  Carpenter, J.F., Randolph, T.W. (2009). “Monoclonal Antibody Interactions 
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                63
FIGURE 2.17. Examples of visible particles in pharmaceutical formulations. Source: 
1.33.
  with Micro- and Nanoparticles: Adsorption, Aggregation, and Accelerated 
  Stress Studies.” J Pharm Sci. 98: 3218-3238. 
2.4 Bee, J.S., Davis, M., Freund, E., Carpenter, J.F., Randolph, T.W. (2010). 
  “Aggregation of Monoclonal Antibody Induced by Adsorption to Stainless 
  Steel.” Biotechnology and Bioengineering. 105(1): 121-129. 
2.5 Bee, J.S., Nelson, S., Freund, E., Carpenter, J.F., Randolph T.W. (2009). 
  “Precipitation of a Monoclonal Antibody by Soluble Tungsten.” J Pharm Sci. 
  98: 3290-3301. 
2.6 Bhattacharjee, S., Elimelech, M., Borkovec, M. (1998). “DLVO Interaction 
  between Colloidal Particles: Beyond Derjaguin’s Approximation.” CCACAA. 
  71(4): 883-903.
2.7 Butt, H.J., Graf, K., Kappl, M. (2003). Physics and Chemistry of Interfaces. 
 1st Edition. Wiley.
2.8 Carpenter, J.F., Randolph, T.W., Jiskoot, W., Crommelin, D.J.A., Middaugh, 
 C.R., Winter, G. (2010). “Potential Inaccurate Quantitation and Sizing of 
 Protein Aggregates by Size Exclusion Chromatography: Essential Need to 
 Use Orthogonal Methods to Assure the Quality of Therapeutic Protein 
 Products.” J Pharma Sci. 99: 2200-2208.
2.9 Chantelau, E.A., Berger, M. (1985). “Pollution of Insulin with Silicone Oil, a 
  Hazard of Disposable Plastic Syringes.” Lancet. 1: 1459. 
2.10 Chantelau, E., M. Berger, Bohlken, B. (1986). "Silicone Oil Released From 
 Disposable Insulin Syringes." Diabetes Care 9(6): 672-673.
2.11 Chi, E.Y., Krishnan, S., Kendrick, B.S., Chang, B.S., Carpenter, J.F., 
 Randolph, T.W. (2003). “Roles of Conformational Stability and Colloidal 
 Stability in the Aggregation of Recombinant Human Granulocyte 
 Colony-Stimulating Factor.” Protein Science. 12: 903-913.
2.12 Chi, E.Y., Weickmann, J., Carpenter, J.F., Manning, M.C., Randolph, T.W. 
  (2005). “Heterogeneous Nucleation-Controlled Particulate Formation of 
  Recombinant Human Platelet-Activating Factor Acetyllhydrolase in 
  Pharmaceutical Formulation.” J Pharma Sci. 94: 256-274.
2.13 Cleland, J.L., Powell, M.F., Shire, S.J. (1993). “The Development of Stable 
 Protein Formulations: A Closer Look at Protein Aggregation, Deamidation, 
 and Oxidation.” Crit Rev Ther Drug Carrier Syst. 10: 307-377.
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                64
2.14 Collier, F.C., Dawson, A.D. (1985). “Insulin syringes and Silicone Oil.” Lancet. 
  2: 611. 
2.15 de Jongh H.H.J., Wierenga, P.A. (2006). “Assessing the Extent of Protein 
  Intermolecular Interactions at Air-Water Interfaces Using Spectroscopic 
  Techniques.” Biopolymers. 82: 384-389. 
2.16 de Young, L.R., Fink, A.L., Dill, K.A. (1993). “Aggregation of Globular 
  Proteins.” Acc Chem Res. 26: 614-620. 
2.17 Dickinson, E. (1999). “Adsorbed Protein Layers at Fluid Interfaces: 
  Interactions, Structure, and Surface Rheology.” Colloids and Surfaces B: 
  Biointerfaces. 15: 161-176. 
2.18 Eftink, M.R., Ghiron, C.A. (1977). “Exposure of Tryptophanyl Residues and 
 Protein Dynamics. Biochemistry. 16: 5546-5551.  
2.19 Eftink, M.R., Ghiron, C.A. (1981). “Fluorescence Quenching Studies with 
 Proteins. Anal Biochem. 114: 199-227. 
2.20 Faude, A., Zacher, D., Muller, E., Bottinger, H. (2007) “Fast Determination of 
 Conditions for Maximum Dynamic Capacity in Cation-Exchange 
 Chromatography of Human Monoclonal Antibodies. J Chromatogr A. 1161: 
 29-35.
2.21 Fesinmeyer, R.M., Hogan, S., Saluja, A., Brych, S.R., Kras, E., Narhi, L.O., 
  Brems, D.N., Gokarn, Y.R. (2009). “Effect of Ions on Agitation- and 
  Temperature-Induced Aggregation Reactions.” Pharmaceutical Reseach. 
  26(4): 903-913. 
2.22 Gabrielson, J. (2006). “Irreversible Association of Monoclonal Antibody with 
  Silicone Oil in Aqueous Formulation Containing Surcrose and Surfactants. In 
  Monoclonal Antibody Aggregation in Therapeutic Formulation: Size and 
  Shape-Distribution Analysis.” Ph.D. Thesis: 100-124. 
2.23  Groza, A., A. Surmeian, et al. (2005). "Infrared spectral investigation of 
 organosilicon compounds under corona charge injection in air at atmospheric 
 pressure." Journal of Optoelectronics and Advanced Materials 7(5): 
 2545-2548.
2.24 Harrison, R.G., Todd, P., Rudge, S.R., Petrides, D.P. (2003). Bioseparations 
 Science and Engineering. New York: Oxford University Press.
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                65
2.25   Hoffman, G. (1977) Iscotables, 7th Edition. Lincoln, Neb., ISCO.
2.26 Hoehne, M., Samuel, F., Dong, A., Wurth, C., Mahler, H., Carpenter, J.F., 
  Randolph, T.W. (2010). “Adsorption of Monoclonal Antibodies to Glass 
  Microparticles”. J Pharm Sci. 1: 1-10. 
2.27 Hogg, R., Healy, T.W., Fuerstenau, D.W. (1966). “Mutual Coagulation of 
  Colloidal Dispersions.” Trans. Faraday Soc. 62: 1638-1651.
2.28 Israelachvili, J.N. (1992). Intermolecular and Surface Forces, 2nd Edition. 
 New York: Academic Press.
2.29 Jakupi, P., Halvorsen, Leaist, D.G. (2004). “Thermodynamic Interpretation of 
 the ‘Excluded-Volume Effect’ in Coupled Diffusion.” J Phys Chem B. 108: 
 7978-7985.
2.30 Jones, L.S., Kaufmann, A., Middaugh, C.R. (2005). “Silicone Oil Induced 
  Aggregation of Proteins.” J Pharm Sci. 94: 918-927. 
2.31 Kerwin, B.A. (2008). “Polysorbates 20 and 80 Used in the Formulation of 
  Protein Biotherapeutics: Structure and Degradation Pathways.” J Pharma 
  Sci. 97(8): 2924-2935.
2.32  Lubiniecki, A., D. B. Volkin, et al. "Comparability assessments of process and 
 product changes made during development of two different monoclonal 
 antibodies." Biologicals. In Press, Corrected Proof.
2.33 Ludwig, D.B., Carpenter, J.F., Hamel, J., Randolph, T.W. (2009). “Protein 
  Adsorption and Excipient Effects on Kinetic Stability of Silicone Oil 
  Emulsions.” J Pharm Sci. 99: 1721-1733. 
2.34 Ludwig, D.B., Trotter, J.T., Gabrielson, J.P., Carpenter, J.F., Randolph, T.W. 
  (2010) “Flow Cytometry: A Promising Technique for the Study of Silicone 
  Oil-Induced Particulate Formation in Protein Formulations.” J Pharm Sci. 
  99(4): 1721-1733.
2.35 Marinova, K. G., R. G. Alargova, Denkov, N.D., Velev, O.D., Petsev, D.N., 
 Ivanov, I.B., Borwankar, R.P. (1996). "Charging of oil-water interfaces due to 
 spontaneous adsorption of hydroxyl ions." Langmuir 12(8): 2045-2051.
2.36 Martin, A.H., Meinders, M.B.J., Bos, M.A., Stuart, M.A.C., van Vliet, T. 
  (2003). “Conformational Aspects of Proteins at the Air/Water Interface 
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                66
  Studied by Infrared Reflection-Absorption Spectroscopy.” Langmuir. 19: 
  2922-2928. 
2.37 Moon, Y.U., Curtis, R.A., Anderson, C.O., Blanch, H.W., Prausnitz, J.M. 
 (2000). “Protein-Protein Interactions in Aqueous Ammonium Sulfate 
 Solutions. Lysozyme and Bovine Serum Albumin (BSA). J Solution Chem. 
 29(8): 699-717.
2.38 Pace, N.C., Trevino, S., Prabhakaran, E., Scholtz, J.M. (2004). “Protein 
 Structure, Stability, and Solubility in Water and Other Solvents.” Phil Trans 
 R Soc Lond B. 359: 1225-1235.
2.39 Pharmacopedia US. (2006). <788> Particulate Matter in Injections. USF-NF, 
 24th edition.
2.40 Randolph, T.W., Jones, L.S. (2002). “Surfactant-Protein Interactions.” Pharm 
  Biotechnology. 13: 159-175.
2.41 Rosenberg, A.S. (2006). “Effects of Protein Aggregates: An Immunologic 
 Perspective.” The AAPS Journal. 8(3): E501-E507.
2.42 Sahin, E., Adeola, A.O., Perkins, M.D., Roberts, C.J. (2010). “Comparative 
 Effects of pH and Ionic Strength on Protein-Protein Interactions, Unfolding, 
 and Aggregation for IgG1 Antobodies.” J Pharma Sci. 99(12): 4830-4848.
2.43 Salinas, B.A., Sathish, H.A., Bishop, S.M., Harn, N., Carpenter, J.F., 
 Randolph, T.W. (2010). Understanding and Modulating Opalescence and 
 Viscosity in a Monoclonal Antibody Formulation.” J Pharma Sci. 99: 82-93.
2.44 Schladitz, C., Vieira, E.P., Hermel, H., Mohwald, H. (1999). “Amyloid-#-Sheet 
  Formation at the Air-Water Interface.” Biophysical Journal. 77: 3305-3310. 
2.45 Sharma, B. (2007). “Immunogenicity of Therapeutic Proteins. Part 2: Impact 
  of Container Closures.” Biotechnology Advances. 25: 318-324.
2.46 Sluzky, V., Tamada, J.A., Klibanov, A.M., Langer, R. (1991). “Kinetics of 
  Insulin Aggregation in Aqueous Solutions Upon Agitation in the Presence of 
  Hydrophobic Surfaces.” Applied Biological Sciences. 88: 9377-9381. 
2.47 Strambini, G.B., Gonnelli, M. (2010). “Fluorescence Quenching of Buried Trp 
  Residues by Acrylamide Does Not Require Penetration of the Protein Fold.” J 
  Phys Chem B. 114: 1089-1093.
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                67
2.48 Timasheff, S.N. (1992). “Water as Ligand: Preferential Binding and Exclusion 
 of Denaturants in Protein Unfolding.” Biochemistry. 31: 9857-9864.
2.49 Thirumangalathu, R., Krishnan, S., Speed Ricci, M., Brems, D.N., Randolph, 
  T.W., Carpenter, J.F. (2009). Silicone Oil- and Agitiation-Induced Aggregation 
  of a Monoclonal Antibody in Aqueous Solution. J Pharm Sci. 98: 3167-3181. 
2.50 Tyagi, A.K., Randolph, T.W., Dong, A., Maloney, K.M., Hitscherich, C., 
  Carpenter, J.F. (2009). “IgG Particle Formation during Filling Pump 
  Operation: A Case Study of Heterogeneous Nucleation on Stainless Steel 
  Nanoparticles.” J Pharm Sci. 98: 94-104. 
2.51 Walstra, P. (1996). Emulsion Stability. In: Bercher P, editor. Encyclopedia of 
 Emulsion Technology. New York: Marcel Dekker. 4: 1-62.
2.52 Wang, W., Nema, S., Teagarden, D. (2010). “Protein Aggregation: Pathways 
 and Influencing Factors.” International J Pharmaceutics. 390: 89-99.
2.53 Wang, W., Singh, S., Zeng, D.L., King, K., Nema, S. (2007). “Antibody 
  Structure, Instability, and Formulation.” J Pharma Sci. 96(1): 1-26.
2.54 Yeung, A., Moran, K., Masliyah, J., Czarnecki, J. (2003). “Shear-Induced 
 Coalescence of Emulsified Oil Drops.” J Colloid and Interface Sci. 265: 
 439-443.
2.55 2010. DOW CORNING 360 Medical Fluid [product information]. Dow 
  Corning Corporation.
2.56 2010. “Flurophores and Their Amine-Reactive Derivatives: Alexa Fluor Dyes 
  Spanning the Visible and Infrared Spectrum.” Molecular Probes: The 
  Handbook. Life Technologies.
2.57 2010. “Probes for Lipids and Membranes.” Molecular Probes: The Handbook. 
  Life Technologies.
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                68
CHAPTER 3: LIGHT SCATTERING ANALYSIS OF HUMANIZED 
MONOCLONAL ANTIBODY INTERACTIONS WITH SILICONE OIL 
EMULSION
3.1   INTRODUCTION
 Flow cytometry is used routinely as a diagnostic tool in clinical and research 
practice. This technique is capable of measuring the properties of individual 
particles through a process called hydrodynamic focusing.3.2,3.4 For particles ranging 
from 0.2 to 150 µm in size, laser light incident upon a particle can either excite 
fluorophores associated with the particle or scatter.3.2,3.4 Accordingly, most 
commercial flow cytometry instruments are equipped to detect the fluorescence at 
various wavelengths as well as both forward- and side-scattered light. 
 A useful principle of flow cytometry is the concept of ‘gating’ whereby one can 
selectively analyze particles of interest and eliminate results generated by 
unwanted particles.3.2,3.4 In typical applications of flow cytometry, heterogeneous 
cell populations are analyzed.3.2,3.4 For this reason, flow cytometry and fluorescence-
activated cell sorting (FACS) are often used interchangeably. Cells types can be 
sorted based on size. Cell size is directly proportional to the forward-scattered light 
intensity.3.2,3.4 Also, cell types can be sorted based on differences in granularity or 
surface topology. Cells with extensive internal compartmentalization or irregular 
surface topologies (e.g. surface roughness, unusual shapes, etc.) tend to have higher 
side-scattered light intensities.3.2,3.4 
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 Fluorescence coupled with light scattering has made flow cytometry a 
versatile tool. The list of developed fluorescence-activated applications of flow 
cytometry is growing. This list includes but is not limited to DNA copy number 
variation analysis (Flow-FISH), protein expression and localization analysis, 
intracellular antigen level determination (e.g. cytokines, secondary mediators, etc.), 
enzyme activity determination, cell membrane potential determination, and 
immunophenotyping.3.2,3.4 
 A nonconventional application of flow cytometry was described in Chapter 2 
and called ‘Fluroescence-Activated Particle Analysis.’ The ability to identify protein 
adsorption to silicone oil and bridging flocculation of silicone oil emulsion occurring 
in a protein formulation is realized in this work. The value of flow cytometry used in 
this context may grow to be a valuable tool used by the pharmaceutical industry in 
formulation development. However, this application of flow cytometry is still in its 
infancy. Only one study to date published by Lugwig et al. has utilized this 
technique in such as fashion.3.3 To build upon the core concept of ‘Fluorescence-
Activated Particle Analysis’ first introduced by Ludwig et al.3.3 and developed 
further in Chapter 2 of this work, this chapter discusses the potential of light 
scattering analysis as a complementary tool to identify protein adsorption and 
bridging flocculation phenomena occurring in pharmaceutical formulations 
containing particulate contaminants such as silicone oil emulsion.
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3.2   MATERIALS AND METHODS
3.2.1   Materials
 In this analysis, the humAbs described in section 2.2.1 were used in the 
buffer conditions listed in section 2.2.2. Silicone oil emulsion was prepared and 
characterized as previously mentioned in sections 2.2.3 and 2.2.4-2.2.5, respectively.
3.2.2   Light Scattering Analysis
 The humAbs and silicone oil emulsion used in this study were fluorescently 
labeled with Alexa Fluor® 647 and BODIPY® 493/503, respectively, as previously 
described in section 2.2.9. Samples were prepared by mixing labeled silicone oil 
emulsion, 0.1 mg/mL labeled protein, and 6X buffer in that order in 2 mL 
polypropylene microcentrifuge tubes. The final protein concentration in each sample 
was 0.01 mg/mL. Samples were incubated statically at room temperature (23ºC ± 
2ºC) for 30 minutes, 3 days, 1 week, 2 weeks, and 1 month. After incubation, 200 µL 
of sample was analyzed using a BD FACSCaliburTM instrument (Becton Dickinson 
and Co. Biosciences, San Jose, CA) equipped with a 488 nm blue argon laser, 635 
nm red diode laser, four fluorescence detectors (FL1 530/30, FL2 585/42, FL3 670LP, 
and FL4 661/16), and 488 nm forward and 90° side light scattering detectors. The 
forward- and side-scattered light intensities for 30,000 particles were detected. Also, 
the fluorescence intensities of Alexa Fluor® 647 and BODIPY® 493/503 for these 
particles were detected.
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3.3   RESULTS
3.3.1   humAb Adsorption to the Silicone Oil-Water Interface
! The adsorption of humAbs to the silicone oil-water interface was verified by 
measuring the intensity of forward and side light scattering as well as the 
fluorescence of labeled silicone oil and protein associated with individual droplets 
(Figure 3.1). Using silicone oil emulsion fluorescently labeled with BODIPY® 
493/503, it was found that the intensity of forward-scattered light was proportional 
to the fluorescence intensity of BODIPY® 493/503, as expected (data not shown). In 
addition, using humAbs labeled with Alexa Fluor® 647, it was also found that the 
intensity of side-scattered light was proportional to the fluorescence intensity of 
Alexa Fluor® 647 (Figure 3.1A). Relating the two types of light scattering, the 
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FIGURE 3.1. Evidence of protein adsorption verified using light scattering and 
fluorescence of labeled silicone oil and humAb. Each of the 30,000 dots on the plot 
represents one silicone oil droplet with adsorbed humAb. (A) Side-scattered light 
intensity is plotted versus the fluorescence intensity of humAb labeled with Alexa 



































intensity of side-scattered light was proportional to the intensity of forward-
scattered light (Figure 3.1B).
3.3.2   Bridging Flocculation of Silicone Oil Emulsion
  The intensities of forward- and side-scattered light were plotted on a log-log 
plot versus one another for different excipient conditions in Figure 3.2. In chapter 2, 
it was found that the scaling exponent form ‘Fluorescence-Activated Particle 
Analysis’ increased significantly over the period of 1 month (Figure 2.5). For silicone 
oil emulsion incubated with humAbs 1-3 for 30 minutes and 1 month, there was a 
shift to larger side-scattering intensities with time, (Figure 3.2A, 3.2B, 3.2C) 
especially in the presence of sodium chloride (Figure 3.2B). In the presence of Tween 
20, there was no noticeable shift in side-scattered light intensity (Figure 3.2D).
3.4   DISCUSSION
3.4.1   humAb Adsorption to the Silicone Oil-Water Interface
 The intensity of forward-scattered light is proportional to the size of the 
silicone oil droplet being analyzed.3.2,3.4 Larger droplets are represented by higher 
intensities of forward-scattered light whereas smaller droplets are represented by 
lower intensities. The interpretation of side-scattered light in this system is more 
complicated. Larger droplets have larger surface areas to adsorb more protein than 
smaller droplets. For larger droplets with more adsorbed protein, there was a 
higher side-scattered light intensity. Consequently, the side-scattered light intensity 
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scaled with the forward-scattered light intensity. This scaling is equivalent to the 
surface area to volume scaling introduced in chapter 2. In that analysis, the 
fluorescence intensity of labeled silicone oil droplet volume scaled with the 
fluorescence intensity of labeled protein adsorbed to its surface. This scaling was fit 
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FIGURE 3.2. Evidence of bridging flocculation of humAb-coated silicone oil 
microdroplets interpreted as shifts in side-scattered light intensity in plots of  s i d e - 
versus forward-scattered light intensity. Each of the 30,000 dots on the plot 
represents one silicone oil droplet with adsorbed humAb for different excipient 
conditions in 10 mM L-histidine at pH 6.0 containing 0.01% (w/v) sodium azide. (A) 
No excipients. (B) 140 mM sodium chloride. (C) 240 mM  sucrose. (D) 0.03% (w/v) 
































































to Equation 7 using a simple geometric scaling relationship to provide insight about 
the shape of objects detected. Here, however, there is no analogous interpretation 
relating forward- and side-scattered light. This plot only serves to verify that 
adsorption of humAbs 1-3 to silicone oil microdroplets occurs. It does not provide 
insight into the shape of droplets directly.
 Plots of forward- versus side-light scattering intensities revealed an 
unexpected result. This plot appeared sigmoidal. A majority of droplets analyzed 
appear in a linear region at smaller particle sizes. This result was expected. 
However, a small minority of larger droplets had higher side-scattering intensities 
than initially anticipated. There are two possible explanations to account for this 
finding. First, there is a small number of  large flocs of silicone oil droplets present 
in solution from the onset of the analysis. As discussed in Chapter 2, the energy 
barrier to coalescence of large silicone oil droplets is seemingly insurmountable. 
However, it may be possible to overcome said barrier in the emulsifying process 
where the large pressures ca. 40 kpsi applied might impart enough energy to induce 
droplet coalescence. Second, in passing through the BD FACSCaliburTM instrument 
(Becton Dickinson and Co. Biosciences, San Jose, CA), the shape of large droplets 
may be distorted. Protein adsorption to the silicone oil-water interface lowers the 
interfacial surface tension of an individual droplet.3.1 This drop in interfacial 
tension might be enough so that at the operating flow rate used the effect of shear 
might be significant. This distortion effect would be more pronounced for larger 
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droplets. Fortunately, for a majority of droplets, this effect appears to be negligible 
making the analysis presented in Chapter 2 valid.
3.4.2   Bridging Flocculation of Silicone Oil Emulsion
 How does the side-scattered light intensity of two equally sized objects, a 
single silicone oil droplet and a floc comprised of multiple droplets, compare? The 
question posed is not trivial. But, it is reasonable to state that the intensity of side-
scattered light depends on the geometry of particles analyzed. Based on the results 
obtained, there appears to be a shift to higher side-scattered light intensities after 
flocculation has occurred. Assuming that a majority of silicone oil droplets are 
initially spherical, flocs formed after a 1 month period are most likely non-spherical. 
The exact shape and size of flocs cannot be determined form this analysis alone. 
But, the difference in the relative size of flocs formed in the presence of different 
formulation excipients can be determined (Figure 3.2). The shift in side-scattered 
light intensity in formulations containing sodium chloride (Figure 3.2B) was greater 
than in formulations containing no excipients (Figure 3.2A) or sucrose (Figure 
3.2C). This most likely means that flocs formed in presence of sodium chloride were 
larger than those formed in the presence of no excipients or sucrose. This finding 
was verified using light microscopy (see Figure 2.14). In the presence of Tween® 20, 
however, there appeared to be no shift in side-scattered light intensity. As droplets 
coated with Tween® 20 approach one another, flocculation may be prevented by 
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steric repulsion.3.5 Hence, there should be no shift in the side-scattered light 
intensity.
3.5   CONCLUSIONS
 The use of light scattering of individual silicone oil droplets offers a new 
means to assess protein adsorption to emulsified droplets and bridging flocculation 
of these droplets. This method provides qualitative information about these 
processes that to date have not been discussed in the literature.3.3 The ability to 
look at individual objects is very appealing in many applications. Used primarily to 
sort cells, light scattering analysis has potential to be used in a variety of 
unexplored capacities as a complementary technique to conventional methodologies.  
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CHAPTER 4: COMPETITIVE ADSORPTION OF HUMANIZED 
MONOCLONAL ANTIBODIES AND SURFACTANTS TO THE 
SILICONE OIL-WATER INTERFACE
4.1   INTRODUCTION
 Selection of a suitable pharmaceutical formulations for therapeutic protein 
products is an important process that is vital to the long-term stability and 
reproducible activity of the drug. Accordingly, the type of buffer and the addition of 
formulation excipients are chosen to maximize protein stability and maintain 
proper functionality of the protein. Excipients used in modern pharmaceutical 
formulations include but are not limited to salts, carbohydrates, polyols, polymers, 
antioxidants, and surfactants. 
 Protein-surfactant interactions are important in many biological applications 
including including drug delivery, cosmetics, and detergent actions.4.7 This 
interaction depends on whether the surfactant in question is ionic or non-ionic. 
Interactions between ionic surfactants and proteins have been studied in the 
literature using steady state and time resolved fluorescence, dynamic light 
scattering, electron-spin resonance, deuterium nuclear magnetic resonance (NMR) 
spectroscopy, excited state protein transfer, and thermodynamic and piezoelectric 
crystal techniques.4.7,4.12-4.13 In pharmaceutical formulations, non-ionic surfactants 
are typically used.4.1,4.8-4.9,4.11,4.14 Using electron paramagnetic resonance (EPR)4.1,4.8 
and analytical ultracentrifugation (AUC)4.8, it has been shown that protein-
surfactant complexes form between protein and non-ionic surfactant. While the 
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formation of a protein-surfactant complex is well established in the literature, the 
complicated nature of this interaction remains poorly understood. 
 In the presence of hydrophobic surfaces, both protein and surfactant can 
adsorb.4.3-4.4 At high bulk concentrations, small-molecule surfactants reduce the 
surface tension more than proteins.4.9 This translates to a greater reduction in the 
interfacial free energy.4.9 Therefore, surfactants have a greater thermodynamic 
affinity for interfaces than proteins.4.9 For a solution containing protein and 
surfactant, there is a competition for adsorption sites at an interface. Because 
surfactants have a higher thermodynamic affinity to adsorb to interfaces than 
protein, it will preferentially bind to an interface forming a densely packed layer.4.3- 
4.4,4.9 A protein can be displaced from an interface by surfactant molecules. Another 
means by which which protein can be removed from an interface by surfactant 
involves the formation of a protein-surfactant complex.4.4 Surfactant molecules can 
bind to hydrophobic patches on protein surfaces.4.1,4.8,4.11 This protein-surfactant 
complex may have a lower thermodynamic affinity for an interface than protein 
alone. Solubilization of the protein-surfactant complex can result in protein 
desorption and replacement by individual surfactant molecules.
 In therapeutic protein formulations, surfactants serve as stabilizing agents to 
prevent protein aggregation.4.9 Surfactants have been shown to adsorb to interfaces 
to eliminate surface-mediated protein aggregation and to prevent agitation-induced 
protein aggregation in solution.4.1,4.8-4.9 In this chapter, the competitive adsorption of 
surfactant and humanized monoclonal antibodies to the silicone oil-water interface 
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was assessed using zeta potential measurements. The zeta potentials of protein 
solutions containing non-ionic surfactants Tween® 20, Tween® 80, and poloxamer 
188 were compared as a function of time.
4.2   MATERIALS AND METHODS
4.2.1   Materials
 In this analysis, the humAbs described in section 2.2.1 were used in the 
buffer conditions listed in section 2.2.2. Silicone oil emulsion was prepared and 
characterized as previously mentioned in sections 2.2.3 and 2.2.4-2.2.5, respectively.
4.2.2   Zeta Potential Analysis
 The zeta potential of humAbs and silicone oil emulsion was assessed using 
laser Doppler velocimetry (LDV) as described in section 2.2.8. A Malvern Zetasizer 
Nano ZS (Worcestershire, United Kingdom) was used to measure the electrophoretic 
mobility of protein and silicone oil dispersions in an applied electric field. The zeta 
potential is calculated using Equation 3. Samples were prepared by mixing silicone 
oil emulsion, 2 mg/mL protein, and 6X buffer in that order in 1.5 mL polypropylene 
microcentrifuge tubes. The final protein concentration in each sample was 0.2 mg/
mL. Samples were incubated statically at room temperature (23ºC ± 2ºC) for 30 
minutes, 3 days, 1 week, 2 weeks, or 1 month. After incubation, a 20:1 dilution of 
silicone oil emulsion in the appropriate buffer was prepared and 0.8 mL of diluted 
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sample was analyzed using a disposable capillary zeta potential cell equipped with 
gold electrodes (Malvern Instruments Ltd., Worcestershire, United Kingdom).
4.2.3   Statistical Analysis
! Average values are reported with standard errors about the mean. Also, 
student’s t-test was used obtain a p-value that was used to compare statistically 
significant differences observed between data sets. A p-value less than 0.05 
indicated that data sets were statistically different.
4.3   RESULTS
4.3.1   Zeta Potential of humAbs-surfactant Solutions
 The measured zeta potential of native humAbs both with and without 
surfactant in the formulation are reported in Figure 4.1. For formulations 
containing surfactant, the measured zeta potential was not statistically different 
from the case where no surfactant was present in formulations containing humAb 2 
and humAb 3 (p > 0.05). Conversely, in formulations containing humAb 1, the 
difference observed in the measured zeta potential between formulations containing 
no surfactant and formulations containing surfactant was statistically significant (p 
< 0.05). In addition, the difference in the measured zeta potential of humAbs 1-3 in 
formulations containing different surfactants were not statistically significant for 
most cases with some exceptions (p > 0.05). Formulations of humAb 1 containing 
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poloxamer 188, humAb 3 containing Tween® 80, and humAb 3 containing 
poloxamer 188 were statistically different than formulations containing no 
surfactant (p < 0.05).  
4.3.2   Competitive Adsorption of humAbs and Surfactants at the Silicone Oil-Water  
 Interface
 For formulations containing humAb and surfactant, the zeta potentials of 
silicone oil emulsion over a 1 month period of time were collected (Figure 4.2, Figure 
4.3, Figure 4.4). The behavior observed was consistent for each humAb and was 
dependent on the identity of the surfactant. In the presence of Tween® 20, the zeta 
FIGURE 4.1. Zeta potential of native humAbs. Data for humAb 1, humAb 2,  a n d 
humAb 3 are labeled accordingly. For each protein, there are four bars representing 
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FIGURE 4.2. Zeta potential of silicone oil emulsion in buffer containing humAb 1 
and 0.03% (w/v) surfactant. (A) Tween® 20. (B) Tween® 80. (C) poloxamer 188. For 
each plot, there are two sets of data:  No protein present, O  Protein present. 
Symbols represent the arithmetic mean of three replicate samples. Error bars 
represent the standard error of the mean. 
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FIGURE 4.3. Zeta potential of silicone oil emulsion in buffer containing humAb 2 
and 0.03% (w/v) surfactant. (A) Tween® 20. (B) Tween® 80. (C) poloxamer 188. For 
each plot, there are two sets of data:  No protein present, O  Protein present. 
Symbols represent the arithmetic mean of three replicate samples. Error bars 
represent the standard error of the mean. 
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FIGURE 4.4. Zeta potential of silicone oil emulsion in buffer containing humAb 3 
and 0.03% (w/v) surfactant. (A) Tween® 20. (B) Tween® 80. (C) poloxamer 188. For 
each plot, there are two sets of data:  No protein present, O  Protein present. 
Symbols represent the arithmetic mean of three replicate samples. Error bars 
represent the standard error of the mean. 
potential of silicone oil emulsion decreased with time and approached that of a 
humAb-free solution. Similar behavior was observed for formulations containing 
Tween® 80. Conversely, the zeta potential remained constant over time for 
formulations containing poloxamer 188 at a value statistically different than that of 
a humAb-free solution (p < 0.05).
4.4   DISCUSSION
4.4.1   Zeta Potential of humAb-surfactant Solutions
 In the literature, there have been many studies to determine if a protein-
surfactant complex forms in solution.4.1,4.7-4.8,4.11-4.13 The results of these reports 
depend on the protein and surfactant used. However, in general, surfactants tend to 
interact with proteins. Accordingly, there was no evidence that this should not be 
true for the proteins and surfactants used in this study. For formulations containing 
humAb 1, the differences in the measured zeta potential for formulations containing 
no surfactant and formulations containing surfactant may represent an indirect 
piece of evidence that such a protein-surfactant complex formed. Even in 
formulations containing humAb 3, while the observable differences were 
statistically insignificant, one cannot rule out the possibility that this interaction 
may take place. The same argument can be made for formulations containing 
humAb 2. An interesting note about humAb 2 was that it was originally formulated 
in a solution containing surfactant then dialyzed into the formulation buffers used 
in this study (see section 2.2.2). If a protein-surfactant complex formed in the 
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original formulation and the complex remained in tact during sample preparation, 
the zeta potential of humAb 2 in the presence of no formulation excipients could 
represent that of the protein-surfactant complex formed and not pure protein as 
was originally assumed. If this was the case, this could partially explain why no 
difference in zeta potential between formulations containing no excipients and 
formulations containing surfactants was observed.
 The aforementioned claims neglected the possibility that it may be the 
surfactants themselves that are responsible for the decreased zeta potential values. 
This would depend on whether the concentration of surfactant was above or below 
the critical micelle concentration (CMC). The CMC of Tween® 20, Tween® 80, and 
poloxamer 188 are 0.007% (w/v)4.9, 0.0017% (w/v)4.9, and 0.1% (w/v)4.15, respectively. 
At a concentration of 0.03% (w/v), Tween® 20 and Tween® 80 are formulated above 
their respective CMC while poloxamer 188 is formulated below its CMC. Above the 
CMC, the formation of micelles which are comprised of roughly 50-100 surfactant 
molecules may influence the measured zeta potential.4.9 In fact, there are 
statistically significant differences in the measured zeta potential of humAb 
formulations containing Tween® 20 or Tween® 80 and formulations containing 
poloxamer 188 (p < 0.05). Whether this is due to the presence of micelles, 
differences in the chemical identity of the surfactants used, binding stoichiometry of 
surfactants to protein, and/or structural differences in the protein-surfactant 
complex remains unknown. However, since the measured zeta potential of all 
humAb formulations containing surfactant are different from that formulations 
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containing no excipients, it is more likely that a protein-surfactant complex was 
forming with only minor observable effects caused by micelle formation.
4.4.2   Competitive Adsorption of humAbs and Surfactants at the Silicone Oil-Water  
 Interface
 The driving force for the adsorption of protein to fluid-fluid interfaces is the 
hydrophobic effect and is described by the interfacial free energy.4.4,4.9 This 
interfacial free energy is proportional to the interfacial surface tension.4.2 At 
increasing surfactant concentrations, the surface tension decreases as a result of 
surfactant adsorption to the interface. At the CMC, the surface becomes saturated 
and micelles form in solution. At concentrations in excess of the CMC, the surface 
tension may be attenuated or may still decrease as a result of additional packing of 
surfactant at the interface.4.2,4.9 Experiments were not conducted in this work to 
verify this claim but this behavior has been observed in similar systems in the 
literature.
 In a solution containing surfactant and protein, there is competition for 
adsorption sites at an interface. In this work, formulations containing silicone oil 
emulsion, protein, and surfactant were prepared. Protein was added prior to 
surfactant in the sample preparation process. As a result, for a brief period of time 
prior to addition of surfactant to the formulation, protein had no competition for 
adsorption sites to the silicone oil-water interface. After the addition of surfactant, 
surfactant adsorption was dependent on its ability to displace adsorbed protein. 
This competition of protein and surfactant for adsorption sites on silicone oil 
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droplets was monitored by measuring the zeta potential at the interface. This 
measurement is not capable of quantifying the amount of protein or surfactant 
adsorption to the interface like the experiments described in section 2.3.2. However, 
it serves as a qualitative method to observe the kinetics of adsorption.
 Looking specifically at solutions of humAbs 1-3 and 0.03% (w/v) Tween® 20, 
0.03% (w/v) Tween® 80, or 0.03% (w/v) poloxamer 188, zeta potential measurements 
implied that the kinetics of humAb displacement was fastest for Tween® 20 and 
slowest for poloxamer 188 (Figure 4.2-4). For Tween® 20 and Tween® 80, the 
concentration of surfactant in the formulation was in excess of each respective 
CMC. At concentrations in excess of the CMC, the surface tension has been shown 
to be greater for Tween 80 than Tween 20 at an hydrophobe-aqueous interface.4.9 
Accordingly, it is reasonable to assert that Tween® 20 lowered the interfacial free 
energy more than Tween® 80 resulting in the the faster displacement kinetics 
observed. For poloxamer 188, however, the concentration used in this study was less 
than the CMC. While it appeared as if adsorption of poloxamer 188 had occurred 
since the measured zeta potential after 30 minutes was less than when no 
surfactant was present in the formulation (see Figure 2.9), there was no change in 
the zeta potential to claim that displacement of humAbs from the interface had 
occurred. But, it is not unreasonable to speculate that this observation may be the 
result of much slower displacement kinetics. If this is true, then the interfacial free 
energy in the presence of poloxamer 188 cannot be compared to that of formulations 
containing Tween® 20 or Tween® 80 in this study. In general, it cannot be 
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concluded in this analysis whether there is displacement of humAbs or humAb-
surfactant complexes from the silicone oil-water interface.
4.5   CONCLUSION
 While more direct measurements would provide better insight into the 
formation of protein-surfactant complexes and protein/surfactant adsorption to 
interfaces, the use of zeta potential measurements has the ability to provide some 
useful qualitative insights into said processes. This method alone is capable of 
making simple comparisons. Used in conjunction with more advanced or 
complicated techniques, zeta potential measurements can be used to obtain a more 
complete description of protein-surfactant complexation and protein/surfactant 
adsorption to interfaces. However, this type of analysis should be used with caution. 
The complex interplay of different charged species in zeta potential measurements 
may make this type of analysis too complicated to be useful in some systems.
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CHAPTER 5: CONCLUSIONS AND FUTURE RECOMMENDATIONS
5.1   FINAL CONCLUSIONS
 In this work, the interaction between three humanized monoclonal antibodies 
with silicone oil emulsion was assessed in the presence of different formulation 
excipients. Using an ‘accelerated’ approach, with an emulsion concentration nearly 
100X that of silicone oil contamination expelled from a syringe, this study sought to 
identify if homogeneous protein aggregation occurred under static conditions. It was 
found that static incubation in the presence of silicone oil emulsion was not a 
sufficient stress to induce aggregation. The presence of different formulation 
excipients did not affect this result. Protein adsorbed to the silicone oil-water 
interface and there was evidence that the conformation of protein at the interface 
was non-native. That analysis could not explain what specifically occurred at the 
interface, but showed that the presence of different formulation excipients did not 
influence this conformational change. As a result of protein adsorption to the 
silicone oil-water interface, emulsion was colloidally destabilized. In addition, due to 
creaming of silicone oil emulsion observed with time, the local concentration of 
emulsion droplets towards the top of the storage container increased. This caused 
bridging flocculation of these droplets which could yield either be sub-visible or 
visible particles (Figure 5.1). This finding was startling. If visible particles formed 
during processing or manufacturing of a commercial therapeutic protein product, 
the whole protein lot may be discarded. This potential problem is alarming to 
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pharmaceutical companies because such a loss could financially cripple a start-up 
company or damage the reputation of a large company. If sub-visible or visible 
particles are present as a formulation is delivered to a patient, the drug could be 
ineffective to treat the disease/disorder, mount an unwanted immune response, and/
or reduce the advertised shelf-life of the product. Use of a surfactant in a 
formulation can serve to prevent the aforementioned problems. Surfactant 
preferentially adsorbed to the silicone oil-water interface. The kinetics of said 
adsorption seems to be dependent on the surfactant concentration and chemical 
identity. During the formulation design process, scientists will have to take this into 
consideration so that the surfactant used in a specific formulation effectively 
displaces most if not all of adsorbed protein from interfaces associated with the 
container/closure system, microparticle contaminants, and/or leachables. If a 
formulation contains the proper surfactant concentration, homogeneous protein 
aggregation and/or heterogeneous protein-contaminant aggregation can be either be 
minimized or completely inhibited.
5.2   FUTURE RECOMMENDATIONS
 The work that has been accomplished is far from complete. More is known 
about protein interactions with silicone oil than before these experiments were 
conducted, but these interactions are still not understood at a fundamental level. 
There are many questions left unanswered. Under what conditions does silicone oil 
induce homogeneous protein aggregation? What is the mechanism of homogeneous 
______________________________________________________
Excipient Effects on Humanized Monoclonal Antibody Interactions with Silicone Oil Emulsion                94
protein aggregation? How do single protein molecules interact with the silicone oil-
water interface at low protein concentrations? What happens when the 
concentration of protein increases such that protein-protein interactions become 
important? There are two important directions that need to be traveled to be able to 
answer some of these questions.
 What happens when the silicone oil-water interface is perturbed? In this 
work, the interface remained static. These experiments need to be repeated for 
agitated samples. Also, experiments geared towards monitoring the effect of 
interfacial compression need to be assessed. End-over-end rotation studies and 
axisymmetric bubble-shape tensiometry are good starting points.
 What happens at the molecular level when the concentration of protein is 
increased from just single molecules to ensembles? Single-molecule total internal 
reflection fluorescence spectroscopy (TIRFM) can provide insight about the 
adsorption of single molecules. This technique can identify different protein 
populations (i.e. monomers, dimers, aggregates) and determine their surface 
residence times and surface diffusion coefficients. What happens as the 
concentration increases? How do protein-protein interactions influence the surface 
residence times and surface diffusion coefficients of different populations? Does 
protein-protein association give rise to new populations (e.g. aggregates)? If so, work 
needs to be done to develop methods to complement front-face fluorescence 
quenching experiments to determine the conformation of adsorbed protein. Methods 
such as circular dichroism (CD), Förster Resonance Energy Transfer (FRET) and 
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hydrogen-deuterium exchange need to be investigated. Lastly, it will be important 
to understand what happens to the functionality of adsorbed protein. Is there a 
correlation between protein adsorption and loss of functionality?
 While it is unlikely that all questions will be answered if all these types of 
experiments were conducted, some questions will be answered. At this stage, it is 
difficult to know exactly what experiments to do without being guided by results. 
The only way to figure out what the next stage will be is to go into the laboratory 
and learn more through experimentation.
FIGURE 5.1. Example of visible particles that can form after protein is incubated 
with silicone oil emulsion. Visible particles were observed after incubation of humAb 
1 in 10 mM L-histidine at pH 6.0 containing 0.01% (w/v) sodium azide and 0.03% (w/
v) Tween® 80 for 72 hours.
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